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Stargardt disease (STGD1) is the most common form of juvenile-onset macular 
dystrophy with the estimated prevalence between 1:8000 to 1:10 000 worldwide 
(Michaelides et al., 2003). Although it is not a very common disease, it causes 
progressive visual loss from childhood or early adolescence affecting sub-
stantially a person’s everyday life.  
The disease is caused by mutations in the ABCA4 gene, which encodes the 
photoreceptor specific transporter vital in the visual cycle (Allikmets et al., 
1997b). The dysfunctional transporter leads to photoreceptor degeneration and 
visual deterioration (Molday and Zhang, 2010). To date, more than 1000 disease 
causing mutations have been described resulting in remarkable allelic and 
phenotypic heterogeneity (Zernant et al., 2014b).  
The modern imaging methods enable to detect and assess phenotypic 
expression on the histological level providing further insights into the patho-
physiology of the disease. Furthermore, multimodal imaging enables to expand 
the phenotypic spectrum permitting to detect new genotype-phenotype asso-
ciations. New insights into the pathophysiology, phenotypes and genotype-
phenotype correlations are essential in the light of ongoing research on gene-
and stem cell therapy in STGD1. Therefore, the present study was designed to 
research the phenotypes and possible phenotype-genotype associations in STGD1 
using multimodal imaging. We assessed and analyzed early stage retinal 
structural changes in young patients with STGD1 and provided further insight 
into the pathophysiology of the disease. In addition, we acquired some new 





2. LITERATURE REVIEW 
2.1. Topographic anatomy of the retina 
Retina is a light-sensitive neural tissue in the inner surface of the eye respon-
sible for converting light into electrical signals, a process called phototrans-
duction (Sung and Chuang, 2010). It is part of the central nervous system, as it 
is embryonically derived from the forebrain (Purves et al., 2004). Direct con-
nection with the brain is ensured by the retinal ganglion cell axons which form 
the optic nerve and transmit the visual impulses to the brain. The optic nerve 
head, also called optic disc, could be visualized with the ophthalmoscope. It 
does not contain any photoreceptors and is an entry site for the major retinal 




Figure 1. Topography of the fundus. The optic nerve head, also called optic disc, is 
formed by axons of the ganglion cells. It is an entrance site for major retinal blood 
vessels. Macula situates between the retinal temporal arcades and is centered by fovea. 
The center of the macula is cone-dominated and the peripheral retina is rod-dominated. 
 
Topographically, retina can be divided into the central and peripheral retina. 
The central retina is called macula and it is located between the retinal temporal 
arteries covering a diameter of approximately 5.5 mm. The macula has central 
depression with the diameter of 1.5 mm called fovea (Yanoff and Duker, 2004). 
Ophthalmoscopically, fovea is recognized by the foveal reflex. The loss of 
foveal reflex could be an early sign of various retinal diseases, including STGD1 
(Reynolds and Olitsky, 2011). The bottom of the fovea is called foveola with 
the diameter of 350 µm. It has the highest concentration of cone photoreceptors 
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providing the highest visual acuity and resolution as well as color vision 
(Yanoff and Duker, 2004, Reynolds and Olitsky, 2011). The peripheral retina is 
rod-dominated and runs from the temporal retinal arteries to the ora serrata 
(Ross and Pawlina, 2011). The main function of the peripheral retina is peripheral 
and night vision (Yanoff and Duker, 2004). 
 
 
2.2. Histological layers and different  
cell types in the retina 
2.2.1. Histological layers of the retina 
The retina has a laminate structure with anatomically distinct layers and dif-
ferent cell types (Ross and Pawlina, 2011). There are 10 distinct histological 
layers in the retina: the pigment epithelium layer (RPE), the photoreceptor 
layer, the external limiting membrane (ELM), the outer nuclear layer (ONL), 
the outer plexiform layer (OPL), the inner nuclear layer (INL), the inner 
plexiform layer (IPL), the ganglion cell layer, the nerve fiber layer and the inner 




Figure 2. Retina is a light- sensitive tissue lining the inner surface of the eye (A: blue). 
It contains a variety of cells responsible for visual phototransduction, processing and 
transmission (B: cones (C) and rods (R), bipolar cells (B), horizontal cells (H), amacrine 
cells (A), Müller cells (M) and ganglion cells (G)). These cells and their axons form 
distinct histological layers within the retina (C): pigment epithelium layer (RPE), 
photoreceptor layer (OS, IS), external limiting membrane (not marked), outer nuclear 
layer (ONL), outer plexiform layer (OPL), inner nuclear layer (INL), inner plexiform 
layer (IPL), ganglion cell layer (GCL), nerve fiber layer (not marked) and inner limiting 
membrane (not marked) (Sung and Chuang, 2010) (with permission from the 
Rockefeller University Press). 
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The outermost layer is the RPE layer, which separates the neural retina from the 
choroid (Ross and Pawlina, 2011). It is a monolayer of RPE cells on the 1–4 µm 
elastic membrane called Bruch’s membrane (Reynolds and Olitsky, 2011). Due 
to the close affinity to each other, a term RPE-Bruch’s membrane complex is 
sometimes used (Karampelas et al., 2013). 
The layer next to the RPE cells is the photoreceptor layer, which consists of 
photoreceptor light sensitive outer segments (OS), responsible of phototrans-
duction, and inner segments (IS) (Ross and Pawlina, 2011). The nuclei of the 
photoreceptors form the outer nuclear layer, which is separated from the photo-
receptor layer by the external limiting membrane (Ross and Pawlina, 2011). The 
ELM is formed by the apical ends of Müller cells forming junctional complexes 
between each other and photoreceptors (Bringmann et al., 2006, Reichenbach 
and Bringmann, 2013), preventing the passage of large molecules into the inner 
parts of the retina (Ross and Pawlina, 2011). Each photoreceptor cell body has 
an axon with synaptic terminal connections with interneuron cells. These con-
nections form the outer plexiform layer responsible for visual impulse trans-
mission. Interneuron cells which have direct connections with photoreceptors 
are bipolar- and horizontal cells, while additional interneurons responsible for 
visual processing are amacrine and interplexiform cells (Reynolds and Olitsky, 
2011, Ross and Pawlina, 2011). Nuclei of the interneurons and Müller cells are 
in the inner nuclear layer and more connections between interneurons (amacrine, 
bipolar, interplexiform) and ganglion cells are formed in the inner plexiform 
layer. Visual impulses are processed and transferred to ganglion cells, which are 
situated in the ganglion cell layer. The axons of the ganglion cells form the nerve 
fiber layer and the optic nerve, which transmit the visual impulse to the brain 
(Purves et al., 2004, Ross and Pawlina, 2011). The innermost layer is called the 
internal limiting membrane and it consists of flattened processes of Müller cells 
(Ross and Pawlina, 2011). 
 
 
2.2.2. Main cell types in the retina 
Retinal pigment epithelium (RPE) 
Retinal pigment epithelial cells are melanin containing cells that form the outer 
blood retinal barrier and separate choriocapillaris from the photoreceptors (Rey-
nolds and Olitsky, 2011). These cells form tight junctions between each other 
preventing free flow of molecules between neural retina and choroid. Instead, 
they facilitate active transport which is essential for the photoreceptor and RPE 
metabolism (Marmor and Wolfensberger, 1998, Strauss, 2005). The retinal 
pigment epithelial cell layer is vital for photoreceptor functioning and survival 
and, in addition to outer blood-retinal barrier function, it serves as a pump, 
keeping the subretinal space dehydrated and neural retina attached to the RPE. 
Furthermore, it supports the retinal development by secreting growth factors 
and cytokines (Strauss, 2005). Different antioxidants in the RPE cells protect 
cells from oxidative damage (Boulton and Dayhaw-Barker, 2001). The retinal 
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pigment epithelium is vital in the visual cycle and retinoid metabolism. It 
participates in the regeneration of chromophores and provides the visual cycle 
with additional retinol by absorbing it from the choroidal circulation (Marmor 
and Wolfensberger, 1998, Strauss, 2005, Simo et al., 2010).  
Photoreceptors are non-dividing cells in an environment of potentially harm-
ful free radicals, therefore regular renewal and turnover is essential for photo-
receptor proper functioning (Sung and Chuang, 2010, Molday and Zhang, 
2010). This reparation mechanism is ensured by the RPE cells, which constantly 
phagocytose photoreceptor outer segment tips, while new ones are formed and 
replaced by the photoreceptors. In fact, 10% of outer segment tips are replaced 
daily (Tsybovsky et al., 2010). In the process of regular turnover of photoreceptor 
outer segments, there is a progressive accumulation of lipofuscin pigment to the 
RPE cells. This pigment is an end-product of outer photoreceptor segment 
degradation that accumulates gradually with age (Kennedy et al., 1995). Chemi-
cally, it is a heterogeneous mixture of lipids, proteins and different fluorescent 
compounds (Kennedy et al., 1995). Lipofuscin is a fluorescent pigment enabling 
to visualize the RPE cells with autofluorescence (AF) imaging (Delori et al., 
1995). Excessive lipofuscin is toxic to the RPE cells and it has a fundamental 
role in the pathophysiology of STGD1 (Cideciyan et al., 2004, Sparrow et al., 
2000, Sparrow and Boulton, 2005). Another pigment in the RPE is melanin, 
which serves as a free radical stabilizer and a light absorber lowering the glare 
(Simo et al., 2010). 
 
Photoreceptor cells 
There are two types of photoreceptor cells in the retina: cones and rods. Cones 
are less numerous than rods, accounting for 3–5% of photoreceptors, but they 
are the major photoreceptor type in the fovea and the only one present in the 
foveola (Sung and Chuang, 2010, Mustafi et al., 2009). Cones are responsible of 
color and high resolution vision in bright light. Rods, on the other hand, domi-
nate the rest of the retina and are responsible for vision in low light intensity 
(Sung and Chuang, 2010).  
The photoreceptor cell consists of the outer segment, the connecting cilia, 
the inner segment, the nucleus and the axon with synaptic terminal (Sung and 
Chuang, 2010, Ross and Pawlina, 2011) (Figure 3). Outer segments in both, 
cones and rods, are cylindrically modified cilia which contain flattened, lamellar-
shaped membrane discs, arrayed perpendicular to the axis of the outer segments 
(Sung and Chuang, 2010). The lipid membrane of these discs contains various 
molecules essential in visual function, including visual pigments and the 
ABCA4 transporter (Ross and Pawlina, 2011, Mustafi et al., 2009). The outer 
segment is connected with the inner segment via the connecting cilia. The inner 
segment has two parts: an outer ellipsoid and inner myeloid part. The myeloid 
region is mainly responsible for protein synthesis, containing Golgi apparatus, 
endoplasmic reticulum and free ribosomes, whereas the ellipsoid region contains 
numerous mitochondria that provide photoreceptors with the adenosine 
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triphosphate (ATP) energy (Ross and Pawlina, 2011, Reynolds and Olitsky, 
2011). A photoreceptor signal is transmitted to the outer plexiform layer via the 




Figure 3. Structure of the rod photoreceptor. Photoreceptors consist of the outer-and 
inner segment, connected with the connecting cilium, the nucleus and synaptic terminal 
(A). The outer segment contains the outer segment discs and inner segment contains 
various organelles vital for photoreceptor functioning (A). The RPE cells participate in 
the outer segment renewal by phagocytosing the tips of the outer segments (A). Outer 
segment contains lamellar discs surrounded by cytoplasm and plasma membrane (B). 
The disc membrane contains various molecules important in phototransduction and the 
visual cycle, including photopigment (not shown) and ABCA4 transporter (C) (Molday 
and Zhang, 2010) (with permission from Elsevier).  
 
Interneuron cells 
The cell bodies of the interneurons are located in the inner nuclear layer. There 
are four types of interneurons responsible for visual signal transmission and 
image processing: bipolar, horizontal, amacrine and interplexiform cells (Ross 
and Pawlina, 2011, Reynolds and Olitsky, 2011). These cells form complex 
neuroretinal circuitries in the OPL and IPL through synapses with photo-
receptors and ganglion cells (Ross and Pawlina, 2011).  
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Ganglion cells 
Ganglion cells are located in the GCL forming contacts with the bipolar and 
amacrine cells (Reynolds and Olitsky, 2011). The axons of the ganglion cells 
form NFL and the optic nerve. The main function of these cells is to conduct 
visual impulses to the brain via the optic nerve. However, there is a small sub-
group of photoreceptive ganglion cells that express photopigment melanopsin. 
These intrinsic photosensitive retinal ganglion cells are non-image-forming, but 
they influence circadian rhythms, pupillary light reflex and sleep (Hattar et al., 
2002, Schmidt et al., 2011, O'Brien et al., 2002).  
 
Glial cells in the retina 
There are three types of glial cells in the retina: Müller cells, astrocytes and 
microglia (Fischer et al., 2010). Müller cells are the major type of glial cells in the 
retina spanning their processes throughout the entire retina filling the most of 
the extracellular space (Bringmann et al., 2006, Reichenbach and Bringmann, 
2013). The nuclei of Müller cells are located in the INL and their basal and 
apical ends form the inner and outer limiting membranes, respectively (Ross and 
Pawlina, 2011). Müller cells provide structural support as well as metabolic 
support to the other retinal cells (Bringmann et al., 2006, Reichenbach and 
Bringmann, 2013). They are able to phagocytose fragments of retinal cells and 
protect photoreceptors from damage by releasing neurotrophic factors and 
antioxidants (Reichenbach and Bringmann, 2013, Bringmann et al., 2006). 
Furthermore, Müller cells participate in the formation and conduction of visual 
impulse by participating in the cone visual cycle and regulating synaptic activity 
in the retina (Reichenbach and Bringmann, 2013, Wang and Kefalov, 2011). 
Müller cells have been shown to act like optical fibers, guiding light through the 
inner retinal layers minimizing the light scattering and improving the quality of 
vision (Franze et al., 2007).  
Astrocytes enter the developing retina via the optic nerve and are mostly 
located in the nerve fiber layer where they envelope the axons of the ganglion 
cells and retinal blood vessels (Chan-Ling, 1994). Astrocytes participate in the 
formation of retinal vessels, the blood-retina barrier and they provide neuro-
tropic as well as mechanical support for degenerating axons (Vecino et al., 2016).  
Microglial cells are tissue-resident phagocytosing cells situating mostly in the 
inner retinal layers. In normal conditions microglia is important in maintaining 
retinal homeostasis. They phagocytose cell debris and secrete growth factors 
(Vecino et al., 2016). However, it has been shown that in various pathological 
conditions, including retinal degenerative diseases like age-related macular 
degeneration (AMD) and retinitis pigmentosa, extensive microglia activation 
leads to inflammation, which adds its detrimental effect on photoreceptors health 
(Vecino et al., 2016, Ma et al., 2009, Ma et al., 2012, Langmann, 2007). In fact, 
it has been shown in a retinitis pigmentosa rat model, that suppressing microglial 
activation may delay photoreceptor death (Noailles et al., 2014). 
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2.3. Physiology of the retina 
2.3.1. Phototransduction cascade 
The process where energy of light is converted into electrical neural signal is 
called phototransduction (Roosing et al., 2014). The process takes place in the 
photoreceptor outer segments via the activation of the visual pigment (Sung and 
Chuang, 2010). The visual pigment is a compound molecule of light sensitive 
chromophore and opsin molecule located in the lipid membrane of outer segment 
discs (Wang and Kefalov, 2011, Palczewski, 2012). The photo-sensitive chromo-
phore is vitamin A aldehyde 11-cis retinal and the molecule is the same in both 
rods and cones. However, there are 4 types of opsin molecules depending on the 
absorption peak (Reynolds and Olitsky, 2011). The visual pigment in rods is 
called rhodopsin and in cones, there are 3 types of cone visual pigments with 
different absorption maxima (Mustafi et al., 2009). The mixture of different 
cones with different visual pigments and absorption peaks result in the ability to 
detect colors (Mustafi et al., 2009). The rods, on the other hand, have only one 
type of visual pigment which is responsible for achromatic vision in dim light 
(Mustafi et al., 2009).  
The visual cascade starts with the capture of a photon and isomerization of 
11-cis retinal to all-trans retinal. This reaction changes the conformation of the 
opsin molecule and activates the photopigment. In the cytosolic side of the disc 
membrane opsin is combined with a G-protein called transducin, which activates 
the enzyme cGMP phosphodiesterase (PDE). This activation reduces the cGMP 
concentration in the cytoplasm resulting in closure of cGMP-gated cation 
channels located in the photoreceptor outer segment plasma membrane. The 
closure of these channels leads to photoreceptor hyperpolarization resulting in 
reduced neurotransmitter glutamate secretion in the synaptic terminal (Palc-
zewski, 2012, Yau, 1994, Yau and Hardie, 2009).  
The restoration of the visual pigment is thereafter crucial. The chromophore 
is restored in the visual cycle and the visual pigment is rebuilt. Deactivation of 
the phototransduction cascade and restoring the photoreceptor sensibility is 
ensured by a cascade of enzymatic reactions (Lamb and Pugh, 2006).  
 
 
2.3.2. Visual cycle and chromophore restoration 
Phototransduction cascade is dependent on the visual cycle, responsible for 
recycling the all-trans-retinal to 11-cis-retinal vital for restoring the visual pig-
ment (Palczewski, 2012). This continuous process takes place in the photo-
receptor outer segments and the RPE cells. In cone system, additional Müller 
cell-based visual cycle has been reported (Reichenbach and Bringmann, 2013, 
Wang and Kefalov, 2011).  
Absorption of photon by visual chromophore isomerizes 11-cis retinal to all-
trans retinal, which is released to the disc lumen. Free all-trans retinal diffuses 
to the cytoplasmatic leaflet of the disk membrane, where NADHPH-dependent 
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retinol dehydrogenase (RDH8) reduces all-trans retinal to all-trans retinol 
(Palczewski, 2012). A fraction of all-trans retinal and 11-cis retinal form com-
pounds with the disk membrane phospholipids which cannot diffuse freely 
across the disk membrane (Quazi et al., 2012, Quazi and Molday, 2014). These 
compounds are flipped out from the disk lumen by ABCA4 transporter after 
which they can be reduced to retinol (Quazi et al., 2012, Quazi and Molday, 
2014). All-trans retinol is transferred out of the photoreceptors to the extra-
cellular compartment, where it binds to the inter-photoreceptor retinoid binding 
protein (IRBP) and is transported to the RPE cells (Wang and Kefalov, 2011, 
Saari, 2012). In the RPE it binds to cellular retinol-binding protein type 1 
(CRBP1) and is esterified by lecithin retinol acyltransferase (LRAT) to all-trans 
retinyl ester (Saari, 2012). This ester is further hydrolyzed and isomerized by 
RPE65 to 11-cis retinol. 11-cis retinol is bound to cellular retinaldehyde-binding 
protein (CRALBP) and oxidized to 11-cis retinal by 11-cis retinol dehydro-
genase after which 11-cis retinal is transported back to the photoreceptors with 
IRBP to regenerate the visual pigment (Saari, 2012). Additional retinol is 
constantly added from the choroid blood circulation by the RPE cells (Chen and 
Heller, 1977).  
 
 
2.4. Stargardt retinal dystrophy 
Stargardt disease is the most common form of inherited macular dystrophy with 
the estimated prevalence of 1:8000 to 1: 10 000 (Michaelides et al., 2003). The 
disease is caused by mutations in the ABCA4 gene, which is on chromosome 1 
and encodes the ABCA4 transporter (Allikmets et al., 1997b). The transporter is 
vital in the visual cycle and the dysfunctional protein leads to lipofuscin over-
accumulation in the RPE cells resulting in RPE and photoreceptor degeneration 
(Sparrow and Boulton, 2005, Cideciyan et al., 2004). The symptoms usually 
start in the first or second decade with progressive visual deterioration (Michae-
lides et al., 2003). Lipofuscin accumulation is responsible for STGD1-asso-
ciated features such as increased fundus autofluorescence (FAF) (Cideciyan et 
al., 2004, Boon et al., 2008), yellow pisciform flecks, and progressive atrophy 
of the outer retinal layers. Early clinical signs of STGD1 are atrophic changes in 
the macula and yellowish flecks, but there is remarkable phenotypic hetero-
geneity within the clinical spectrum of STGD1 (Fishman et al., 1999, Fishman, 
1976, Fujinami et al., 2013d, Cella et al., 2009, Lois et al., 2001, Westeneng-
van Haaften et al., 2012). Distinguishing STGD1 from other phenotypically 
similar diseases is often difficult with just a clinical exam, therefore ABCA4 
genetic screening and application of several imaging methods, such as SD-OCT 





Figure 4. Different imaging methods of the retina in the healthy eye: color photo (A), 
an autofluorescence image (B) and an optical coherence tomography image (C). The 
SD-OCT enables to visualize different retinal layers (inset): outer retinal layers are 
retinal pigment epithelium (RPE), the interdigitation zone (IZ), the ellipsoid zone (EZ), 
the external limiting membrane (ELM) and the outer nuclear layer (ONL) (from Edward 
S. Harkness Eye Institute). 
 
Stargardt disease is autosomal recessive dystrophy requiring mutations on both 
chromosomes to cause the disease (Allikmets et al., 1997b), however, complete 
sequencing of ABCA4 coding and intron-exon boundaries reveal two ABCA4 
mutations in only 65–70% of patients and one ABCA4 mutation in 15–20% of 
patients (Zernant et al., 2011). Detection of only one ABCA4 mutation with 
“typical” STGD1 phenotype could be explained from both genetic and clinical 
aspects. The second mutation could be large deletion, insertion or deep intronic 
variant, which all elude the routinely used screening methods, such as direct 
PCR-based sequencing, or the phenotype could be a phenocopy caused by 
mutation(s) in other genes (Zernant et al., 2011, Zernant et al., 2014b). Further-
more, the second mutation could be present in modifier genes or in promoter/ 
enhancer regions near the ABCA4 gene which influence the ABCA4 expression 
(Zernant et al., 2011, Westeneng-van Haaften et al., 2012).  
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2.4.1. ABCA4 function in visual cycle and pathogenesis of STGD1 
ABCA4 is a photoreceptor specific transporter vital for the visual cycle. It is a 
member of the ATP-binding cassette transporter superfamily and has two nuc-
leotide binding domains (NBD) for ATP binding and hydrolyzing, two trans-
membrane domains (TMD) and two exocytoplasmatic domains (ECD) for 
substrate binding and transportation (Molday and Zhang, 2010). The protein is 
encoded by the ABCA4 gene on chromosome 1 and is located in the outer seg-
ment disc rims of rods and cones (Sun and Nathans, 1997, Molday et al., 2000) 
(Figure 3).  
In the process of photo-transduction, all-trans retinal is released. The molecule 
contains an aldehyde group, which makes it highly reactive and potentially 
harmful to the photoreceptors. Therefore all-trans retinal needs to be detoxified 
and reduced to all-trans retinol (Quazi and Molday, 2014, Quazi et al., 2012). 
The enzyme essential for this reaction is retinol dehydrogenase 8 (RDH8) in the 
cytoplasm of the photoreceptor outer segments (Rattner et al., 2000). Therefore, 
all-trans retinal has to get out from the disc lumen to be accessible to the RDH8. 
Most of the all-trans retinal diffuses freely across the lipid bilayer but a fraction 
form compounds with the membrane phospholipid called phosphatidylethanol-
amine. The formed compound is called N-retinylidene-phosphatidylethanol-
amine and it cannot diffuse across disc membrane by itself, but employs the 
ABCA4 transporter for that purpose (Quazi et al., 2012). The ABCA4 transporter 
flips N-retinylidene-phosphatidylethanolamine from the lumen to the cyto-
plasmatic leaflet of the disc membranes where it diffuses back to phosphatidyl-
ethanolamine and all-trans-retinal (Quazi et al., 2012). Thereafter the all-trans 
retinal can be reduced to all-trans retinol by RDH8. In addition, ABCA4 
transports free phosphatidylethanolamine in the same direction (Quazi et al., 
2012). Recently it has been showed that similar process is true for 11-cis retinal, 
where excess 11-cis retinal may form compounds with phosphatidylethanol-
amine and ABCA4 transports N-11-retinylidene-phosphatidylethanolamine out 
from the disc lumen (Quazi and Molday, 2014). Therefore, ABCA4 transporter 
helps to clear the photoreceptors from the excessive 11-cis and all-trans retinal, 
both highly reactive and potentially toxic molecules to the photoreceptors 
(Quazi et al., 2012, Quazi and Molday, 2014).  
Mutations in the ABCA4 gene lead to dysfunctional ABCA4 transporter 
resulting in N-retinylidene-phosphatidylethanolamine accumulation and for-
mation of bisretinoid complexes in the lumen side of disc membrane (Molday 
and Zhang, 2010). There is constant renewal of the photoreceptor outer seg-
ments by the RPE cell phagocytosis. During the process these diretinoid 
complexes deposit to the lysosomes of the RPE cells where major lipofuscin 
fluorophore, A2E (N-retinylidene-N-retinylethanolamine) is formed and 
deposited (Sparrow et al., 2008, Tsybovsky et al., 2010, Ben-Shabat et al., 2002). 
A2E containing lipofuscin has harmful effects on the RPE cell functioning via 
various effects. These include lysosomal dysfunction (Holz et al., 1999), 
membrane disruption (Sparrow et al., 1999), loss of antioxidant effectivity 
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(Shamsi and Boulton, 2001), photo-toxicity (Schutt et al., 2000, Sparrow et al., 
2000), immune dysregulation (Zhou et al., 2009, Zhou et al., 2006) and DNA 
damage (Sparrow et al., 2003). As the RPE cells are vital in photoreceptor 
function, progressive RPE cell degeneration leads to photoreceptor death.  
The excessive lipofuscin accumulation is believed to be the hallmark of the 
pathogenesis in STGD1 (Sparrow and Boulton, 2005, Cideciyan et al., 2004, 
Burke et al., 2014), however, there is increasing evidence that neuro-inflam-
mation in the retina plays also an important role in the pathogenesis of retinal 
degenerations (Zhou et al., 2009, Kohno et al., 2013, Xu et al., 2009, Radu et 
al., 2011, Ma et al., 2012, Langmann, 2007, Zhou et al., 2006). Photo-exposure 
to A2E and all-trans retinal dimers leads to formation of photo-oxidation 
products which are capable of activating complement and induce low-grade 
inflammation (Zhou et al., 2009, Zhou et al., 2006, Sparrow et al., 2000, Schutt 
et al., 2000). Furthermore, the migration of microglia and macrophages into 
subretinal space has been described in Abca–/– mice (Radu et al., 2011, Kohno et 
al., 2013) and it has been demonstrated that the deposition of A2E to the RPE 
cells and microglia increases microglial activation and alters the complement 
regulation in vitro as well as in vivo (Ma et al., 2013, Kohno et al., 2013, Zhou 
et al., 2009, Zhou et al., 2006). Microglia accumulates the bisretinoids and lipo-
fuscin primary by phagocytosing surrounding degenerating photoreceptors and 
RPE cells (Ma et al., 2013, Lei et al., 2012, Kohno et al., 2013, Xu et al., 2009). 
In addition, the RPE cells themselves modulate microglia by producing chemo-
kines after phagocytosing the photoreceptor outer segments (Kohno et al., 
2013). Therefore, the activation of immune cascade affects the environment and 
different cell types in the outer retina contributing to the pathogenesis of STGD1.  
Furthermore, it has been shown that excess all-trans retinal and possibly 11-
cis retinal can cause photoreceptor damage directly (Maeda et al., 2009, Maeda 
et al., 2014, Maeda et al., 2012, Chen et al., 2012). However, there is still debate 
whether the primary cells affected in STGD1 are RPE cells or photoreceptors 
(Sparrow and Boulton, 2005, Cideciyan et al., 2004, Duncker et al., 2014, Gomes 
et al., 2009, Burke et al., 2011). 
 
 
2.4.2. Structural and functional assessment of the retina in STGD1 
Spectral-domain optical coherence tomography and  
retinal structural changes in STGD1 
Optical coherence tomography (OCT) is a non-invasive imaging method 
enabling to create cross sectional retinal images in vivo (Sakata et al., 2009) It 
uses light waves to measure their reflection time delay and intensity from 
different retinal structures by comparing it with the reference reflection path 
(Drexler and Fujimoto, 2008). This enables to visualize different retinal layers 
correlating with retinal histology and detect even minor disease-associated 
structural changes (Spaide and Curcio, 2011, Staurenghi et al., 2014). The 
image quality and resolution of OCT has improved substantially within the last 
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decade providing researches new perspectives in terms of clinical research and 
understanding of the retinal diseases.  
The spectral-domain optical coherence tomography (SD-OCT) retinal images 
exhibit different intensity bands correlating with the anatomical layers of the 
retina (Spaide and Curcio, 2011, Staurenghi et al., 2014). Four distinct hyper-
reflective fine bands are visualized in the outer retina associated with Müller 
cells, photoreceptors and RPE cells (Spaide and Curcio, 2011) (Figure 4, C). 
The outermost hyper-reflective band represents RPE/Bruch`s membrane complex 
formed mainly by the RPE cells. Anteriorly, a fine elusive band is attached to 
the RPE layer. The band is called the interdigitation zone and is possibly formed 
by the RPE apical processes enveloping cone outer segment tips. The third band 
is called the ellipsoid zone, thought to represent the ellipsoid zone of the 
photoreceptor inner segment just above the cilia. The hyper-reflectivity is 
thought to be caused by intensely packed mitochondria in this region (Spaide 
and Curcio, 2011, Staurenghi et al., 2014). Disappearance of this band represents 
photoreceptors integrity loss correlating well with visual acuity decline (Wong 
et al., 2012, Testa et al., 2012). The innermost hyper-reflective band represents 
the external limiting membrane formed by junctional complexes of Müller cell 
apical ends to each other and with photoreceptors (Spaide and Curcio, 2011, 
Staurenghi et al., 2014).  
Stargardt disease is retinal dystrophy affecting mostly the outer retina layers: 
the RPE and the photoreceptor associated layers (Burke et al., 2011, Duncker et 
al., 2014, Park et al., 2015, Ergun et al., 2005) (Figure 5). It has been shown that 
greater photoreceptor loss on OCT imaging corresponds to lower visual acuity 
(Ergun et al., 2005), furthermore, the ellipsoid zone integrity correlates also well 
with other studies which assess photoreceptor health including multifocal electro-
retinography (mfERG), full-field electroretinography (ffERG) and microperi-
metry (Testa et al., 2012). However, changes in retinal thickness have also been 
detected in the inner retinal layers. Extrafoveal inner nuclear layer thickening 
associated with the regions of outer nuclear layer thinning have been noted, 
probably due to the retinal remodeling following the photoreceptor loss (Huang 
et al., 2014). Furthermore, changes in peripapillary nerve fiber layer thickness 
in STGD1 have been demonstrated (Genead et al., 2011, Pasadhika et al., 2009). 
These findings confirm that retina is a complex tissue with vigorous commu-
nication between different cell types and changes in the outer retina lead to 
inner retina remodeling and laminopathy (Huang et al., 2014).  
Choroidal thickness measurements in STGD1 have revealed that the mean 
subfoveal total choroidal thickness as well as subfoveal large choroidal vessel 





Figure 5. “Classical” phenotype in STGD1. The color photo of the fundus exhibits 
bull’s-eye like atrophic lesion in the macula and yellowish flecks throughout the entire 
fundus (A, arrows). Macular atrophy corresponds to hypo-autofluorescent central lesion 
on the fundus autofluorescence image due to the atrophy of the RPE layer. Hyper-AF 
dots are seen throughout the fundus (white arrow), representing flecks. Hypo-
autofluorescent dots are seen on the nasal side representing resorbed flecks (B). 
Disruption and atrophy of the outer retinal layers are seen in the macula on SD-OCT 
image (C) (from Edward S. Harkness Eye Institute). 
 
Fundus autofluorescence imaging in STGD1 
The major source for short-wavelength FAF signal is lipofuscin which is 
accumulated in the RPE cells (Delori et al., 1995, Sparrow and Boulton, 2005). 
Lipofuscin contains a mixture of fluorophores, which could be excited with a 
light source. After the excitation it emits back signal with longer wave length, 
which can be detected and recorded. The signal is generated by illuminating the 
fundus with an argon laser source within blue spectrum (488 nm) and the 
resultant FAF signal is recorded with confocal scanning laser ophthalmoscope 
(cSLO) with bandpass filter having short wavelength cutoff 495 nm (Keane and 
Sadda, 2014, Schmitz-Valckenberg et al., 2008).  
The lipofuscin concentration in the RPE cells increase with age, but in 
STGD1 it is pathologically extensive (Delori et al., 2001, Burke et al., 2014), 
therefore FAF imaging enables to detect early stage pathological changes in 
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STGD1, including an increased FAF signal and characteristic fleck patterns 
(Cideciyan et al., 2004, Lois et al., 2004, Fujinami et al., 2013b, Burke et al., 
2014). As FAF imaging provides information about the health and integrity of 
the RPE cells, absence of or the reduced FAF signal indicates mostly to RPE 
atrophy or death (Holz et al., 2001, Boon et al., 2008).  
Cideciyan et al proposed a model of ABCA4 disease sequence where initially 
there is an accumulation of lipofuscin leading to a progressive increase in the 
FAF signal and hyper-AF fleck formation in the posterior pole followed by FAF 
signal reduction and loss in later stages due to the RPE dysfunction and death 
accompanied by slowing of the retinoid cycle and increasing photoreceptor 
degeneration (Cideciyan et al., 2004).  
As STGD1 cases have very variable phenotype, different FAF patterns have 
been described, whereas the most typical is central hypo-autofluorescent (hypo-
AF) lesion reflecting chorioretinal macular atrophy surrounded by small hyper-
autofluorescent (hyper-AF) pisciform flecks (Boon et al., 2008) (Figure 5). 
Measurements of FAF signal intensity in STGD1 with quantitative AF 
demonstrate that different genotypes provide different fluorescence levels and 
certain genotype-phenotype associations are possible (Duncker et al., 2014). 
 
Functional assessment of the retina with electroretinography in STGD1 
Retinal function is assessable with many different methods, while one of the most 
objective methods is electroretinography (ERG). Full-field ERG enables to assess 
the general function of the photoreceptors as well as the function of other retinal 
cells in the inner nuclear layer (Holder et al., 2010). Depending on the stimuli 
and background illumination it is possible to record the function of cone and rod 
photoreceptors separately. The full-field ERG generates mass response of the 
cones, rods or both, therefore in isolated macular disease the full-field ERG is 
usually normal (Holder et al., 2010). Consequently, multifocal ERG (mfERG) or 
pattern ERG (PERG) is essential in assessing the macular function (Holder et 
al., 2010). 
Multifocal ERG examines the spatial aspect of the cone system function in the 
central retina mapping the electrical activity of cones in the central visual field 
(Holder et al., 2010, Kretschmann et al., 1998). Pattern ERG, on the other hand, 
does not use light stimulus, but black and white checkerboard instead, assessing 
the central retinal photoreceptor function as well as ganglion cell function 
(Holder et al., 2010).  
Stargardt disease is macular dystrophy suggesting that there should be abnor-
malities in the PERG and mfERG, but normal full-field ERG. However, STGD1 
shows a wide range of full-field ERG abnormalities (Fishman, 1976, Lois et al., 
2001, Zahid et al., 2013, Fujinami et al., 2013a), based on which the disease could 
be divided into 3 separate groups: Group 1 exhibits PERG abnormalities, but 
normal full-field photopic and scotopic responses, Group 2, in addition to PERG 
abnormality, exhibits changes in photopic ERG and Group 3 exhibits decreased 
responses in both photopic and scotopic ERG responses (Lois et al., 2001). 
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Furthermore, the differences in groups are not explained on the basis of dif-
ferences in age of onset and duration of the disease, suggesting that these could 
be separate phenotypic subgroups rather than different stages of the disease 
progression (Lois et al., 2001). Indeed, it would be reasonable to assume that 
the phenotype might predict cone-rod function on full-field ERG, meaning that 
lesions confined to the macula have normal ERG, while more wide-spread 
disease has more affected ERG, (Fishman, 1976, Zahid et al., 2013, Cella et al., 
2009) but it is not always the case. The retinal phenotype with macular lesion 
could have very prominent changes in full-field ERG and more prominent fundus 
changes could have normal full-field ERG (Oh et al., 2004, Lois et al., 2001).  
Full-field ERG may have prognostic value in terms of STGD1 progression 
since it has been shown that abnormalities in maximum stimulation A-and B- 
wave amplitudes have significantly higher average rate of scotoma progression 
compared with the patients with normal full-field ERG (Zahid et al., 2013). 
Fujinami et al showed that patients with STGD1 who present initially with normal 
full-field ERG (Group1) have most favorable prognosis, as only 22% of patients 
have ERG deterioration, while in patients in ERG groups 2 or 3 have ERG 
deterioration in 65% and 100% of patients, respectively. Association between 
best-corrected visual acuity (BCVA) and ERG as well as between ERG and age 
of onset was also detected, meaning that lower BCVA was associated with more 
affected ERG and the earlier the onset, the more affected was the ERG (Fujinami 
et al., 2013a).  
Multifocal ERG is a sensible tool for detecting early functional abnormalities 
of the macula in STGD1 even before apparent morphological macular change or 
visual acuity loss, furthermore, the area of dysfunction is usually larger than 
predicted by morphological studies (Kretschmann et al., 1998).  
 
 
2.4.3. Phenotypic heterogeneity in STGD1 
The clinical expression of the disease was first described by a German ophthal-
mologist Karl Stargardt in 1909, but the association with the ABCA4 gene was 
discovered almost 90 years later (Allikmets et al., 1997b, Stargardt, 1909). 
Since then, more than 1000 disease causing mutations in the ABCA4 gene have 
been found resulting in remarkable phenotypic and genotypic heterogeneity in 
ABCA4-associated retinopathies (Zernant et al., 2014b). In addition to pheno-
typic heterogeneity in STGD1 in terms of clinical expression, fundus and 
electroretinography findings as well as in age of onset, mutations in ABCA4 
have also been reported in cone-rod dystrophy (Cremers et al., 1998, Maugeri et 
al., 2000), autosomal recessive retinitis pigmentosa (Cremers et al., 1998, 
Martinez-Mir et al., 1998) and AMD (Allikmets et al., 1997a). However, it has 
to be noted that autosomal-recessive cone-rod dystrophy is also considered as a 
phenotypic version of STGD1 (Lois et al., 2001). Sometimes the term fundus 
flavimaculatus is used in a subgroup of patients, with widespread fundus flecks 
without apparent macular atrophy, but currently it is considered as a phenotypic 
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variant of the STGD1 rather than a separate entity (Fishman, 1976, France-
schetti and Francois, 1965, Michaelides et al., 2003). Overall, STGD1 typically 
begins with early macular atrophic changes and yellowish flecks at the posterior 
pole, but there is remarkable phenotypic heterogeneity with variable age of 
onset and clinical expression (Michaelides et al., 2003). Most of STGD1 patients 
have the disease onset in the first two decades of life (Michaelides et al., 2003) 
with the central visual loss, reduced dark adaption (Fishman et al., 1991) and 
disturbances in the color vision (Mantyjarvi and Tuppurainen, 1992, Vanden-
broucke et al., 2015), but it could vary largely (Westeneng-van Haaften et al., 
2012).  
Based on disease onset, STGD1 has been divided into early-onset and late-
onset disease (Westeneng-van Haaften et al., 2012, Yatsenko et al., 2001, 
Lambertus et al., 2015) or childhood-onset and adult-onset STGD1 (Fujinami et 
al., 2015). Phenotypes in early-onset STGD1 are more severe compared with the 
late-onset STGD1 (Fujinami et al., 2015, Lambertus et al., 2015). It has been 
shown that childhood-onset STGD1 is associated with more severe and faster 
visual acuity deterioration and more common generalized cone and rod system 
dysfunction compared with adult-onset STGD1 (Fujinami et al., 2015). Late-
onset STGD1 patients have usually milder phenotype with adult or even elderly 
age of onset, better visual acuity and slower progression (Westeneng-van Haaften 
et al., 2012). Many late-onset patients exhibit foveal sparing phenotype (Weste-
neng-van Haaften et al., 2012).  
Foveal sparing is a sub-phenotype where foveal region remains relatively 
intact maintaining partial or full function despite relatively advanced disease 
(Fujinami et al., 2013d, van Huet et al., 2014). The foveal sparing phenotype is 
not specific to STGD1, but it has been described in other retinal degenerations 
as well (Duncker et al., 2015, Querques et al., 2016, Forte et al., 2013). In 
STGD1, there has been a report of tendency to higher frequency of p.R2030Q 
and lower incidence of p.G1961E variant (Fujinami et al., 2013d), however 
another study did not confirm the association (van Huet et al., 2014).  
A less common phenotype in STGD1 is optical gap, also known as foveal 
cavitation or optically empty lesion (Cella et al., 2009, Leng et al., 2012, Ritter 
et al., 2013). The phenotype is detectable on SD-OCT as focal subfoveal loss of 
ellipsoid zone reflectivity, representing subfoveal photoreceptor loss leaving an 
optically empty space (Leng et al., 2012). The phenotype is not specific to 
STGD1; it has also been described in solar retinopathy (Jain et al., 2009), laser 
induced retinal injury (Zhang et al., 2016), rod monochromatism (Greenberg et 
al., 2014) and RP1L1 maculopathy (Park et al., 2010).  
Based on phenotypic expression, multiple grading systems for the disease 
have been suggested. Fishman et al divided STGD1 patients into 4 phenotypic 
stages: Stage 1 disease represents central macular atrophy with para- or peri-
foveal flecks; Stage 2 represents flecks throughout the entire posterior pole 
often extending anterior to the vascular arcades and/or nasal to the optic disc, 
Stage 3 presents with mostly resorbed flecks and Stage 4 represents widespread 
RPE and chorioretinal atrophy throughout the fundus (Fishman, 1976).  
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Electrophysiological abnormalities were noted from Stage 3 indicating that 
phenotype affects the ERG. Lois et al, on the other hand, did not find that ERG 
abnormalities correlated with age of onset or disease duration, suggesting that 
there could be distinct ERG phenotypes depending on abnormalities in cone and 
rod function (Lois et al., 2001).  
Flecks in STGD1 are not universal, but may develop later in the disease 
course (Fujinami et al., 2015, Lambertus et al., 2015). In some patients with 




2.4.4. Genotype-phenotype associations in STGD1 
Genotype-phenotype associations are difficult to determine due to extensive 
allelic heterogeneity. Furthermore, determining the severity of specific allele is 
impeded because compound heterozygous patients harbor two different alleles 
and the number of patients sharing the same allelic combinations is generally low. 
The phenotypic expression of the same genotype may vary between different 
cases or even within the same pedigree, indicating a possibility of modifying 
genes and environmental factors (Lois et al., 1999, Schindler et al., 2010, 
Michaelides et al., 2007). Previous studies have hypothesized that phenotype 
severity, including age of onset, is determined by mutations effect on ABCA4 
activity, meaning that the lower the ABCA4 residual activity the more severe is 
the phenotype (Sun et al., 2000, Shroyer et al., 1999, van Driel et al., 1998). 
Missense mutations mapping outside the functional ABCA4 region, probably 
retaining partial ABCA4 activity, have shown to be associated with milder 
disease and later-onset STGD1 (Yatsenko et al., 2001), while mutations 
abolishing ABCA4 function, exhibit severe phenotype with early-onset pan-
retinal disease (Cremers et al., 1998, Wiszniewski et al., 2005, Fujinami et al., 
2013a, Fujinami et al., 2015). Fujinami et al demonstrated further that 
childhood-onset STGD1 have higher portion of deleterious ABCA4 variants 
compared with adult-onset STGD1 and 71% patients with two deleterious ABCA4 
variants in childhood-onset STGD1 were in the ERG Group 3 (Fujinami et al., 
2015).  
Mutations in the ABCA4 gene may phenotypically express as STGD1, cone-
rod dystrophy (Cremers et al., 1998, Maugeri et al., 2000) or retinitis pig-
mentosa-like disease (Cremers et al., 1998, Martinez-Mir et al., 1998). It has been 
shown that the most severe mutations abolishing the ABCA4 function result in 
retinitis pigmentosa-like dystrophy, while milder mutations result in cone-rod 
dystrophy or STGD1 (Heathfield et al., 2013). It has to be noted that autosomal 
recessive cone-rod dystrophy caused by ABCA4 dysfunction has also been 
classified as a phenotypic variant of STGD1 belonging to ERG Group 3 (Lois et 
al., 2001, Fishman, 1976, Fujinami et al., 2013a). Moreover the “classical” 
STGD1 may progress to retina-wide disease, affecting both rod and cone 
induced full-field ERG responses, diagnostic to cone-rod dystrophy (Fujinami et 
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al., 2013a). However, some studies have shown that the ABCA4 function hypo-
thesis does not always apply, and probably some additional factors contribute to 
the phenotypic expression (Cideciyan et al., 2009, Burke et al., 2012b).  
Probably the most studied variant in STGD1 is the p.G1961E allele. This is 
not unexpected, as the p.G1961E mutation is the most frequent disease-causing 
ABCA4 allele seen in approximately 10% of STGD1 patients of European origin 
(Burke et al., 2012a). The p.G1961E allele has been associated with bull’s eye 
maculopathy and milder phenotypes in STGD1 (Cella et al., 2009, Fishman et 
al., 1999, Fujinami et al., 2013c). Cella et al studied a cohort of patients with at 
least one p.G1961E allele and none of the patients exhibited generalized cone or 
rod function loss (Cella et al., 2009). All patients presented with bull’s eye 
maculopathy without flecks. They concluded that the p.G196E allele in either 
homozygosity or compound heterozygosity confers a milder phenotype with 
bull’s eye lesion, later disease onset and absence of generalized retinal dys-
function (Cella et al., 2009). However, a larger study with patients homozygous 
for p.G1961E demonstrated that it is not always the case and exceptions are 
possible (Burke et al., 2012a). Furthermore, it is believed that p.G1961E has a 
“dominant” effect over the other allele in trans, because even if the second 
mutation is “severe”, the phenotype tends to be “milder” (Burke and Allikmets, 
2013, Burke et al., 2014). Additionally, patients carrying the p.G1961E allele 
have lower FAF signal level and absence of the dark choroid phenomenon 
indicating lower lipofuscin accumulation with this allele (Burke et al., 2014, 
Fishman et al., 1999). 
 
 
2.4.5. Differential diagnosis of STGD1 
It is often difficult to distinguish STGD1 by an ophthalmic examination from 
other phenotypically similar retinopathies, especially if these exhibit similar 
hyper-AF flecks. One example is multifocal patter dystrophy which frequently 
simulates STGD1 (Duncker et al., 2015, Boon et al., 2007). It is an autosomal 
dominant dystrophy caused by mutations in the PRPH2 gene (Boon et al., 2007). 
Two other autosomal dominant Stargardt-like macular dystrophies (STGD3 and 
STGD4), caused by mutations in ELOVL4 and PROM1 genes, respectively, have 
been described (Palejwala et al., 2016, Zhang et al., 2001, Kniazeva et al., 1999).  
Stargardt disease could exhibit bull’s eye macular lesion even without 
characteristic flecks (Cella et al., 2009, Fujinami et al., 2015), therefore all con-
ditions exhibiting bull’s eye maculopathy should be considered as a differential 
diagnosis. These include cone (rod) dystrophy, central areolar choroidal 
dystrophy, age-related macular degeneration, chronic macular hole, chloroquine/ 
hydroxychloroquine (HCQ) retinopathy, olivopontocerebellar atrophy and ceroid 
lipofuscinosis (Regillo et al., 2007). Cone (rod) dystrophy is a diagnosis made 
via ERG and can be caused by many genes, including ABCA4 (Cremers et al., 
1998, Maugeri et al., 2000), which is/are mostly considered as phenotypic 
variant(s) of STGD1 (Lois et al., 2001). Central areolar choroidal dystrophy has 
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autosomal dominant inheritance, adult onset and is caused by mutation in 
PRPH2 (Hoyng et al., 1996). Late-onset STGD1 is sometimes confused with 
AMD (Westeneng-van Haaften et al., 2012, Burke et al., 2012a), while bull’s 
eye maculopathy in younger individuals with neurologic deficit could suggest 
olivopontocerebellar atrophy or lipofuscinosis (Wright et al., 2006).  
Hydroxychloroquine is an anti-malaria drug commonly used in the treatment 
of various systemic autoimmune disorders which may cause retinopathy with 
bull’s eye lesion exhibiting “flying-saucer” sign on SD-OCT (Chen et al., 2010). 
The term “flying-saucer” sign is a variant of foveal sparing, referring to abrupt 
disruption of the EZ band in the parafoveal region and thinning of the outer 
nuclear layer, forming a so-called “flying saucer” configuration (Chen et al., 




3. AIMS OF THE STUDY 
1) To assess and analyze early stage retinal structural changes in young patients 
with STGD1 (Paper I). 
2) To find, describe and analyze uncommon SD-OCT phenotypes in STGD1 
and to assess retinal function in these patients (Papers II, III). 





4. MATERIALS AND METHODS 
4.1. Study subjects and clinical evaluation 
All studies were conducted at the Department of Ophthalmology of the 
Columbia University, using clinical and genetic database involving patients 
with clinical diagnosis and genetic confirmation of STGD1 found to have one 
or two disease causing mutations in the ABCA4 gene. Within this cohort, SD-
OCT and FAF (AF; 488 nm) images were available for 179 patients in Paper I 
and Paper II. New patients with STGD1 were constantly added to the database 
and followed and re-imaged once a year, therefore, for Paper III, 200 patients 
with the set of imaging data were available. 
 Each patient underwent a complete ophthalmic examination by a retinal 
specialist, including slit-lamp examination and dilated fundus examination. The 
function of the retina was assessed with full-field and multifocal ERG, while the 
structure was examined using color fundus photography, FAF imaging and SD-
OCT. The best corrected visual acuity (BCVA) was detected in all patients, except 
for only one patient in Paper I, where data about BCVA were not available.  
The estimated disease duration was defined to be the period from the 
reported age of symptomatic onset to the age at first examination. 
 
Phenotypic expression and outer retinal abnormalities  
in young patients with STGD1 (Paper I) 
Due to our clinical observation that the abnormalities in the ELM develop in 
younger patients who in general have shorter disease duration and earlier disease 
stage, we included all patients with STGD1 from the group of 179 patients who 
presented to the Retina Division for SD-OCT and FAF imaging before the age 
of 20. Therefore, these patients were imaged relatively soon after the disease 
onset (mean disease duration was 3.2 years). A total of 26 STGD1 patients (mean 
age, 12.9 years; range, 5–19 years) satisfied the inclusion criteria. The thickness 
and reflectivity of the ELM and EZ were measured and the data were compared 
with the data obtained from the SD-OCT-s from 30 age-matched controls (age 
range, 4–20 years; mean age, 12.5 years). Full-field ERG recordings were 
available and analyzed in 19 patients. 
 
Structural and Genetic Assessment of the ABCA4-Associated  
Optical Gap Phenotype (Paper II) 
Spectral-domain OCT images of 179 STGD1 patients were analyzed and 15 
patients with the optical gap phenotype were identified and included to the study. 
Phenotypic staging was carried out and defined by two independent graders for 
each patient. Clinical characteristics and ABCA4 mutation profile were described 
and analyzed for all patients. 
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Recessive Stargardt disease phenocopying hydroxychloroquine  
retinopathy (Paper III) 
Spectral-domain OCT images of 200 patients with STGD1 were retrospectively 
assessed and 8 patients with a variant of foveal sparing SD-OCT phenotype 
usually associated with hydroxychloroquine (HCQ) retinopathy were detected. 
Clinical characteristics and genetic profile of the STGD1 patients with the SD-
OCT phenotype were described and analyzed. 
 
 
4.2. Retinal imaging 
Spectral-domain OCT scans, FAF and near-infrared reflectance images were 
acquired using the Spectralis HRA+OCT device (Heidelberg Engineering, 
Heidelberg, Germany). Fundus autofluorescence images were acquired by 
illuminating the fundus with an argon laser source (488 nm) and viewing the 
resultant fluorescence through a band-pass filter with a short wavelength cutoff 
at 495 nm. Color fundus photos were obtained with an FF 450plus Fundus 
Camera (Carl Zeiss Meditec AG, Jena, Germany). Foveal fixation in Paper II 
was assessed using fundus camera with fixation needle. 
 
Quantitative image analysis  
In Paper I, quantitative analyses of the ELM and EZ were conducted on high-
resolution SD-OCT scans of the right eye of 24 STGD1 patients (mean age, 12.9 
years; range, 5–19 years) and 30 age- matched controls (mean age, 12.5 years; 
range, 4–20 years).  
The sampling area for each measurement was assigned to a position half the 
distance between the foveal center and the nasal edge of the optic disc, a location 
measured with the ruler tool within the ophthalmic software (Heidelberg Explorer 
Software; Heidelberg Engineering (Figure 6, A). Analysis of the designated 
area in the macula was not possible for two patients (P10, P23) due to progressed 
outer retina atrophy. Thickness and reflectivity values were averages between 
measurements made manually by two independent observers with the ophthalmic 
software (Heidelberg Engineering) (Figure 6, B and C).  
Reflectivity of the ELM and EZ on SD-OCT was assessed by obtaining the 
maximum pixel gray values (peaks) corresponding to the ELM and EZ of a 
vertically positioned pixel intensity profile (reflectivity profile) perpendicular to 
the RPE layer. Pixel intensity profiles were generated and analyzed with ImageJ 
software (http://imagej.nih.gov/ij/; available in the public domain of the National 
Institutes of Health, Bethesda, MD, USA) (Figure 6, C). Longitudinal changes 





Figure 6. Quantitative analyses of ELM and EZ thickness and reflectivity on SD-OCT. 
(A) The sampling area for each measurement was assigned to half the distance between 
the foveal center and the nasal edge of the optic disc. (B) Thickness measurements 
where made manually by two independent observers. (C) Comparative band reflectivity 
values were obtained from the maximum pixel gray values (peaks) corresponding to the 




Full-field scotopic and photopic electroretinograms were obtained according to 
the International Society for Clinical Electrophysiology of Vision (ISCEV) 
standards (Marmor et al., 2009) using the Espion visual electrophysiology system 
(Diagnosys LLC, Littleton, MA, USA) and silver-impregnated fiber electrodes 
(DTL; Diagnosys LLC, Littleton, MA, USA).  
Multifocal ERG in Paper 2 was recorded and analyzed with the VERIS system 
(VERIS EDI, San Mateo, CA, USA) using Burian-Allen contact electrode. Test 
was performed according to the standards and guidelines of the International 
Society for Clinical Electrophysiology of Vision (Hood et al., 2012).  
Based on the full-field ERG findings, patients were divided into 3 groups: 
Group1 exhibited pattern electroretinography abnormalities, but normal full 
field photopic and scotopic responses, Group 2 exhibited changes in isolated 
photopic function and Group 3 exhibited significant dysfunction in both the 
scotopic and photopic systems (Lois et al., 2001). 
 
4.4. Genetic analyses 
In Paper I, ABCA4 screening was first performed with the ABCA4 microarray 
for all patients. If none or one ABCA4 mutations were identified, then further 
screening was performed with next-generation sequencing (NGS).  
In Papers II and III all patients were screened for ABCA4 variants by complete 
sequencing of all coding and intron/exon boundaries of the gene by either 
Sanger sequencing or by NGS. The next-generation sequencing was performed 
either with Fluidigm Custom Amplicon protocol (Access Array; Fluidigm, 
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South San Francisco, CA; http://www.fluidigm.com/products/access-array.htnl) 
followed by sequencing on 454 GS-FLX Fluidigm sequencer as described 
before (Zernant et al., 2011) or with the Illumina TruSeq Custom Amplicon 
protocol (Illumina, San Diego, CA), followed by sequencing on Illumina MiSeq 
platform (Illumina MiSeq; Illumina, Inc). The next-generation sequencing reads 
were analyzed and compared to the reference genome GRCh37/hg19, using the 
variant discovery software NextGENe (SoftGenetics LLC, State College, PA).  
All detected possibly disease-associated variants were confirmed by Sanger 
sequencing and analyzed with the Alamut software (http://www.interactive-
biosoftware.com). Segregation of the variants with the disease was analyzed if 
family members were available. The allele frequencies of all variants were 
compared to the Exome Variant Server (EVS) dataset, NHLBI Exome 
Sequencing Project, Seattle, WA, USA (http://snp.gs.washington.edu/EVS/; 




The utilized statistical software was SPSS Statistics 16.0 for Windows (SPSS, 
Inc.; Chicago, IL, USA) and the data compared in the studies were deemed 
statistically significant when p < 0.05.  
In Paper I, the statistical comparisons of the ELM and EZ measurements 
between study subjects and age–matched controls were done by unpaired 
Student t-tests (two-tailed). Agreement on manual measurements of the ELM 
and EZ was assessed between two independent observers with intraclass 
correlation coefficients (ICC).  
The statistical comparison of the age at time of examination, age of onset 
and estimated disease duration between the p.G1961E and non-p.G1961E 
patients in Paper II was performed by unpaired Student t-test (two-tailed). 
Pearson’s chi-square test was used to analyze the significance of the presence of 




All patients were enrolled in the study after consenting under the protocol 
#AAAI9906. The protocol was approved by the Institutional Review Board at 
Columbia University and adhered to the tenets set out in the Declaration of 






5.1. Phenotypic expression and outer retinal abnormalities 
in young patients with STGD1 (Paper I) 
The study cohort consisted of 26 young patients with early-onset STGD1 
imaged before age 20 years. 
 
 
5.1.1. Clinical and genetic evaluation of the young STGD1 patients 
The mean disease duration was 3.2 years, ranging between 0.5 to 8 years. In 7 
patients the data about disease duration was not available, because the patients 
did not remember the age when the symptoms started or the disease was 
detected accidentally. Best-corrected visual acuities ranged from 20/20 to 
20/400 in both eyes. At least two (expected) disease-causing mutations in 
ABCA4 gene were identified in all patients, except one sibling pair (P2 and P3) 
and P20 in whom only one disease associated allele was found (Table 1).  
 
 
5.1.2. Phenotypic evaluation of the young STGD1 patients 
At the time of examination 54% of patients exhibited central macular atrophy 
with or without perifoveal flecks (Fishman stage 1), while 46% of patients 
exhibited more widespread flecks often extending anterior to the vascular 
arcades (Fishman stage 2). P12 presented asymptomatically with no apparent 
changes on funduscopy and was discovered through an affected sibling. Eight 
patients (31%) presented with bull’s eye maculopathy phenotype. 18 patients 
(69%) patients presented either initially with, or eventually developed yellow 
pisciform flecks. Fundus autofluorescence imaging revealed the presence of 
“fine macular dots” in 14 patients (54%). Qualitative thickening of the ELM on 
SD-OCT was noted in all patients. Full-field ERG results were available for 19 
patients, of which 13(68%) exhibited normal generalized scotopic and photopic 
function (Group 1) and six (32%) had amplitudinal reduction and implict time 
delays in the photopic system (Group 2). Patients were grouped into Group 1 or 





















OD OS Allele 1 Allele 2 
P1 10 20/30 20/25 1 1 1 p.E160* p.R1108C 
P2 10 20/70 20/80 2 2 0.5 p.[L541P;A1038V]  
P3 7 20/40 20/30 1 1 ND p.[L541P;A1038V]  
P4 13 20/80 20/50 2 1 ND p.P1380L c.5714+5G>A 
P5 14 20/200 20/150 1 1 0.5 p.P1380L c.5714+5G>A 
P6 13 20/40 20/50 2 1 ND p.[L541P;A1038V] p.L2027F 
P7 8 n/a n/a 1 n/a ND p.[L541P;A1038V] p.L2027F 
P8 10 20/40 20/80 1 1 1 p.R1108C p.Q1412* 
P9 14 20/100 20/100 2 1 0.5 p.T972N p.L2027F 
P10 9 20/150 20/400 2 1 ND c.5312+1G>A p.R2030* 
P11 15 20/200 20/200 2 2 3 p.L2027F p.R2077W 
P12 5 20/30 20/40 1 n/a ND c.5018+2T>C p.G1961E 
P13 10 20/200 20/200 2 2 4 p.[L541P;A1038V] p.R1640W 
P14 12 20/200 20/200 2 2 6 p.[L541P;A1038V] p.R1640W 
P15 16 20/200 20/200 2 n/a 8 p.K346T p.T1117I 
P16 9 20/150 20/150 1 n/a 1 p.P1380L p.G1961E 
P17 18 20/40 20/150 1 1 3 p.P1380L p.G1961E 
P18 18 20/150 20/150 2 1 4 p.[L541P;A1038V] p.L2027F 
P19 16 20/150 20/150 1 n/a 6 p.G863A p.[W1408R;R1640W]
P20 18 20/125 20/50 2 2 5 p.R1640W p.V1693I (benign) 
P21 12 20/50 20/50 1 1 6 p.W821R p.C2150Y 
P22 17 20/40 20/100 1 n/a 3 p.G1961E c.6729+4_+18del 
P23 10 20/400 20/400 2 2 3 c.885delC p.R537C 
P24 19 20/20 20/20 1 n/a ND p.G863A c.5898+1G>A 
P25 16 20/80 20/100 1 1 4 p.A1773V p.G1961E 
P26 17 20/150 20/200 1 1 2 p.K1547* p.R2030Q 
ND, not determined; n/a, not available. 




5.1.3. Longitudinal changes in the cohort 
Progression data following two or more time points, one year apart, revealed 
variable changes in each patient. Out of 17 patients who initially presented with 
yellow pisciform flecks, two (P2, P9) had very fast progression from small 
hyper-AF flecks around the fovea to partially resorbed flecks beyond the vascular 
arcades; two others (P11, P15) presented with larger hyper-AF flecks throughout 
the macula and developed flecks beyond the vascular arcades, exhibiting partial 
darkening and resorption of some flecks; and one (P8) appeared unaffected and 
developed small hyper-AF flecks around the fovea. Serial SD-OCT imaging 
revealed a receding EZ and apparent RPE thinning over time at the leading edge 
of the central lesion of atrophy. No apparent changes to the ELM were observed 
in this time period; however, a consistent discordance between the position of 
EZ loss and ELM loss was noted. In almost all observed cases, the EZ appeared 
to recede earlier than the ELM on SD-OCT. 
 
 
5.1.4. Quantitative analysis of outer retinal layers  
in young STGD1 patients 
The ELM and EZ thickness as well as reflectivity was measured and compared 
with the age-matched control subjects. The measurements of ELM and EZ 
thickness as well as reflectivity of the bands were done by two independent 
observers and the calculated ICCs revealed acceptable agreement between both 
observers for each measurement (Table 2). 
 
Table 2. Intraclass correlation coefficients of SD-OCT measurements. 
  STGD1 Patients Unaffected Individuals 
Sampled ELM Thickness (µm) 0.948 (0.782–0.982) 0.836 (0.659–0.922) 
Sampled ELM Reflectivity  
(gray value) 
0.938 (0.861–0.973) 0.920 (0.830–0.962) 
Sampled EZ Thickness (µm) 0.796 (0.472–0.915) 0.874 (0.738–0.940) 
Sampled EZ Reflectivity  
(gray value) 
0.857 (0.675–0.937) 0.876 (0.736–0.941) 
The 95% confidence intervals are in parentheses; SD-OCT, spectral domain-optical coherence 
tomography; ELM, external limiting membrane; EZ, ellipsoid zone; STGD1, Stargardt disease. 
 
Qualitative and quantitative analyses of the ELM and EZ bands on SD-OCT 
revealed consistent and significant difference between STGD1 patients and age-
matched controls. The thickness of the ELM band in the measured area was 
significantly greater (mean = 17.69 µm, SD = 4.23) in STGD1 patients, particu-
larly in the three younger patients (P3, P10, P16), compared with unaffected 
individuals (mean = 11.45 µm, SD = 1.08, p < 0.0001; Table 3 and Figure 7, 
A). A mild downward trend in ELM thickness with age was noted (r2 = 0.21), 
while ELM thickness appeared to be relatively constant in the control group.  
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We also measured the EZ thickness in the same area and detected that STGD1 
patients exhibited a thinner (mean = 16.65 µm, SD = 2.34, p < 0.0001) EZ com-
pared with unaffected individuals (mean = 20.64 µm, SD = 1.34, p < 0.0001; 
Table 3 and Figure 7, B).  
To assess the thickness of the ELM relative to the EZ, the calculated ratios 
of ELM/EZ in the patients were compared with the control ratios. Ratios of 
ELM/EZ in unaffected individuals fell consistently within the 0.5 range, 
indicating a 1-to-2 relationship between the thickness of the ELM and EZ on 
SD-OCT. Thickness ratios of ELM/EZ in STGD1 patients, while more variable, 
were significantly greater (p < 0.0001) than the control group (Table 3 and 
Figure 7, C).  
Band reflectance on SD-OCT was assessed by comparing the brightest pixel 
(vertical gray value profile peak) of the ELM and EZ bands (Table 3). To 
compare patients while accounting for scan normalization, reflectance values 
were compared as ratios for each patient. The reflectance ratios in STGD1 
patients were significantly greater (p < 0.0001) than those of the control group 
(Table 3 and Figure 7, D). Quantitation in two patients, P10 and P23, was 
impossible due to progressed atrophy in the measurement area; however, the 
ELM thickening and increased reflectivity was qualitatively observed in their 
respective SD-OCT scans in less-affected areas of the macula.  
 
Table 3. Quantitative thickness and reflectivity sampling in SD-OCT scans. 
  SD-OCT Thickness (µm) SD-OCT Reflectivity (gray value) 




STGD1 Control STGD1 Control STGD1 Control STGD1 Control 
Mean 16.65 20.64 17.69 11.45 170.40 210.58 139.5 81.15 
Standard 
deviation 
2.34 1.34 4.23 1.08 19.24 31.32 24.40 22.76 
Standard 
error 
0.48 0.24 0.86 0.20 3.98 5.72 4.98 4.16 
 SD-OCT Thickness (µm) SD-OCT Reflectivity 
Unpaired 
t-test 




ELM-EZ ratio: STGD1  
vs control 
p-value < 0.0001 < 0.0001 < 0.0001 
 ELM-EZ ratio: STGD1  
vs. control 
    
  < 0.0001     
SD-OCT, spectral-domain optical coherence tomography; ELM, external limiting membrane; EZ, 
ellipsoid zone; STGD1, Stargardt disease. 
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Figure 7. Quantitative analyses of the ELM and EZ band thickness and reflectivity on 
SD-OCT. Thickness (µm) of the ELM and EZ were measured at a consistent position 
within the macula in 24 STGD1 patients (red circles) and 30 age-matched controls (gray 
circles). Analysis of the designated area of the macula was not possible in two patients 
(P10, P23) due to progressed atrophy. (A) Thickness of the ELM in the measured areas 
was significantly greater (p < 0.0001) in STGD1 patients compared with unaffected 
individuals, (B) whereas the thickness of the EZ at the same location was thinner in 
STGD1 (p < 0.0001). (C) The relative ELM/EZ thickness (calculated as the ratio between 
the ELM and the EZ) within normal subjects consistently fell within 0.5 (EZ band is 
approximately two times thicker than the ELM band); an overall larger and more 
variable relative ELM/EZ thickness (p < 0.0001)was observed in STGD1 patients. (D) 
Relative reflectivities of the ELM-to-EZ bands where significantly more intense 
(p < 0.0001) in STGD1 patients compared with normal controls.  
 
 
5.2. Optical gap phenotype in STGD1 (Paper II) 
The optical gap, also referred as optically empty lesion or foveal cavitation (Leng 
et al., 2012), is a retinal phenotype representing a focal loss of subfoveal photo-
receptors detectable on SD-OCT as a focal loss of ellipsoid reflectivity leaving 
an optically empty space under the fovea (Leng et al., 2012).  
We detected the optical gap phenotype in 15 STGD1 patients from the 
cohort of 179 patients with the available SD-OCT images and characterized the 
optical gap phenotype in STGD1 according to its developmental stages. We 





5.2.1. Clinical and phenotypic evaluation of STGD1 patients  
with the optical gap phenotype 
Fifteen patients were detected and evaluated from a cohort of 179 patients 
(Table 4). The mean age of the patients with the optical gap phenotype was 
23.5 years (range, 12–30 years) and the reported age of the disease onset was in 
the second and third decades of life (mean age of onset of 19.4 years) 
corresponding to the mean symptomatic disease duration of 4 years. One patient 
(P1) was asymptomatic at the time of presentation.  
Thirteen patients exhibited a bull’s eye-like phenotype on color fundus photos. 
Parafoveal flecks were observed in 6 patients (12 eyes). Fixation was assessed 
at the first visit in 10 patients. Eighteen eyes from 10 patients had extrafoveal 
fixation, while P10 and P11 had preserved central fixation in the right eye only 
due to the eccentric localization of the optical gap and preserved ellipsoid zone 
in the center. 
All except two patients (P1, P2) had undergone full-field ERG at initial visit 
and were categorized to Group 1 (Lois et al., 2001) having age-matched normal 
scotopic and maximal responses. Multifocal ERG data were available in six 
patients, while half of them had data available only for the right eye. Each 
patient had decreased responses in the central 5° to 15° on mf ERG, showing 
much larger affected area than SD-OCT and FAF images predicted. 
 
 
5.2.2. Structural staging of the optical gap phenotype with SD-OCT 
Based on clinical observation and follow-up data from SD-OCT images we 
staged the optical gap phenotype and divided the patients into three disease 
development groups (Figure 8).  
 
Stage 1: Moderate ellipsoid zone disruptions.  
The initial stage represented distinctive structural breaks in the EZ and degra-
dation of photoreceptors in the foveal outer retina on SD-OCT forming an 
optically empty zone fulfilled with remnants of the ellipsoid (Figure 8, P2). 
The ONL thinning in the macula was present in all patients, while the ELM and 
the RPE were intact. Five patients (10 eyes) of the 15 patients presented with 
this, Stage 1, disease.  
Best corrected visual acuity was relatively mildly affected ranging from 
20/25 to 20/60 (mean 20/40) and appeared to be dependent on the degree of EZ 
band loss.  
Fundus autofluorescence images showed a dark roundish lesion with reduced 































































































































































































































































































































































































































































































































































































































































































































































Figure 8. Developmental stages of the optical gap lesion in STGD1. 
 
Stage 2: Expanded foveal cavitation. 
A widened empty cavity characterized by total absence of the EZ was observed 
on SD-OCT in eight patients (Figure 8, P12). Some granular deposits or 
residual debris were attached to the concavely arched ELM in the lesion. A 
relatively larger, horizontally-elongated lesion resembling an elliptical bull’s 
eye lesion within a hyper-AF halo was observed on FAF imaging in six patients, 
while P6 had speckled macular appearance on FAF image, which corresponded 
with fleck-like deposits in the central macula.  
Mean visual acuity in Stage 2 patients was 20/80 spanning a spectrum from 
20/30 to 20/150. In two patients (P10, P11) the optical gap lesion was atypically 
eccentrically off-centered, preserving the EZ at the fixation point. Therefore, 
these patients maintained the BCVA of 20/40 and 20/30 in the right and left 
eyes, respectively and central fixation in the right eye. 
 
Stage 3: Inner retinal collapse. 
A structural collapse of the inner retinal layers into the vacant ellipsoid space 
with residual spaces along the edge of the previously occupied gap lesion was 
observed in P14 (Figure 8, P14), where we had clear evidence on OCT images 
showing transition from stage 2 to stage 3. In the retrospective review of the 
whole cohort, we detected another patient with similar structure with the residual 
gap spaces along the edges of the lesion, P15.  
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Visual acuities appeared similar to stage 2 patients, while the BCVA of P15 was 
relatively preserved at 20/30 in both eyes, possibly explained by relatively spared 
outer retina fragment in the foveal center seen on FAF and SD-OCT images. 
  
5.2.3. Longitudinal analysis of the optical gap phenotype in STGD1 
The longitudinal data enabled us to understand how the optical gap structure 
behaves over the time and made possible to create the staging system for the 
optical gap phenotype.  
Longitudinal data and images were available and analyzed in 8 patients (P5-
P8 and P12-P15). The initial and current stage is presented in Table 4.  
Inter-stage progression was observed in patients P5, P14 and P15, while 
other patients for whom the data were available remained Stage 2 within 1.5 to 
3 years follow-up (Figure 9). P5 initially presented with mild photoreceptor 
disorganization and Stage 1 optical gap was detected after one year. The BCVA 
progressed from 20/30 and 20/25 to 20/60 in both eyes. Her older sibling (P6) 
exhibited a more advanced Stage 2 optical gap lesion. P14 progressed from Stage 
2 to Stage 3 within 2 years retaining a stable BCVA of 20/100 in both eyes. 
Progression of Stage 3 gap to progressive atrophy within 1 year was seen in P15. 
 
 
Figure 9. Gantt chart summarizing the ABCA4-associated optical gap stage progression 
and duration. Longitudinal OCT imaging was available for eight patients in the study 
cohort. Patient 5 presented with minor EZ changes (Stage 0) and progressed bilaterally 
to Stage 1 optical gap a year after initial examination. Patients 6, 7, 8, 12 and 13 initially 
presented and remained in Stage 2 over a range of 1.5 to 3 years. Patients 15 progressed 
to an atrophic stage following Stage 3, while P14 exhibited unilateral progression from 
Stage 2 to Stage 3 in the left eye. 
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5.2.4. Phenotype-genotype association in STGD1  
with the optical gap phenotype 
The cohort of 15 patients included 11 unrelated cases and four sibling pairs. 
Segregation analysis was available for 11 patients. At least two (expected) 
disease-causing variants were identified in each patient. In unrelated cases, 91% 
were compound heterozygous for the p.G1961E variant (Table 5). With the 
exception of P13, the optical gap was not observed in the SD-OCT scans of any 
other non-p.G1961E patients (n = 131) whose age at time of examination, age 
of onset and estimated disease duration were not statistically different from 
those of p.G1961E (n = 48) patients (Table 6). The allele frequency of 
p.G1961E allele in patients with the optical gap phenotype was 46.7%, while in 
the entire STGD1 cohort of 179 patients (157 unrelated individuals) it was 
13.4%, showing statistically highly significant difference (p < 0.0001).  
 
Table 5. Summary of genetic data of ABCA4-associated optical gap patients. 
Patient #,  
Gender 
ABCA4 Mutations 
DNA level Protein level 
1, F†* c.[286A>G];[5882G>A] p.[(N96D)];[(G1961E)] 
P2, F†* c.[286A>G];[5882G>A] p.[(N96D)];[(G1961E)] 
P3, M† c.[1622T>C(;)3113C>T(;)5882G>A] p.[(L541P(;)A1038V(;)G1961E)] 
P4, M† c.[1622T>C(;)3113C>T(;)5882G>A] p.[(L541P(;)A1038V(;)G1961E)] 
P5, F†* c.[1622T>C;3113C>T];[5882G>A] p.[(L541P;A1038V)];[(G1961E)] 
P6, F†* c.[1622T>C;3113C>T];[5882G>A] p.[(L541P;A1038V)];[(G1961E)] 
P7, F†* c.[1622T>C];[5882G>A] p.[(L541P)];[(G1961E)] 
P8, F†* c.[1622T>C];[5882G>A] p.[(L541P)];[(G1961E)] 
P9, F* c.[5882G>A];[6448T>C] p.[(G1961E)];[(C2150R)] 
P10, F* c.[4139C>T];[5882G>A] p.[(P1380L)];[(G1961E)] 
P11, M c.[5318C>T(;)5882G>A] p.[(A1773V(;)G1961E)] 
P12, F* c.[5196+1056A>G];[5882G>A] p.[?];[(G1961E)] 
P13, M* c.[2461T>A];[6449G>A] p.[(W821R)];[(C2150Y)] 
P14, F c.[5882G>A(;)6229C>T] p.[(G1961E(;)R2077W)] 
P15, F* c.[1622T>C;4328G>A];[5882G>A] p.[(L541P;R1443H)];[(G1961E)] 
†Sibling pairs: P1and P2, P3 and P4, P5 and P6, P7 and P8. 





Table 6. Comparison of clinical data between p.G1961E and non-p.G1961E patients 
from the entire STGD1 cohort of 179 patients.  
  p.G1961E mutation(s) n:  
48 





Mean SD Median Range Mean SD Median Range p-value 
Age 34.5 18.6 28.5 5 to 78 36.9 17.8 37.6 7 to 83 > 0.4 
Age of 
Onset 
20 10.1 17.5 2 to 55 19.4 12.1 16.5 4 to 52 > 0.7 
Disease 
Duration 
15.6 17.8 8.5 0.1 to 71 17.8 14.9 14.3 0.2 to 63 > 0.4 
Fundus 
phenotype 
Patients (n) Patients (n)  
BEM  39 42  
Other† 9 89  
Optical 
Gap  
14 1  
Statistical comparison is made by unpaired Student t-test (two-tailed); p-value is calculated 
between p.G1961E and non-p.G1961E patients;  
SD, standard deviation; BEM, bull’s eye maculopathy; † Other than bull’s eye lesion (minor 
macular changes to more advanced atrophy). 
 
  
5.3. A subtype of foveal sparing phenotype in STGD1 
resembling HCQ retinopathy (Paper III) 
We detected and analyzed 8 unrelated patients with STGD1 from the cohort of 
200 STGD1 patients who exhibited a variant of foveal sparing phenotype on 
SD-OCT described previously with HCQ retinopathy. This transient HCQ 
retinopathy SD-OCT phenotype represents an outer retinal thinning in the 
parafoveal region with the relative sparing of the foveal region, colloquially 
termed the „flying saucer“ sign (Chen et al., 2010). A retrospective clinical and 
genetic evaluation of these patients was done and structural analysis of the 
retina was carried out. Three patients with STGD1 were having classical bull’s 
eye lesion similar to HCQ retinopathy. 
 
 
5.3.1. Clinical and genetic evaluation of the patients 
The cohort (age range, 10–57 years) consisted of ethnically diverse individuals 
who presented to the Retina Clinic for a retinal evaluation. All patients presented 
to the clinic without a medical history of HCQ use (Table 7). Five patients (P2, 
P4, P5, P6 and P7) reported no visual symptoms but were referred for a retinal 
evaluation after routine optometric visits, while P3 complained of mild bilateral 
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metamorphopsia and P8 complained of halos in front of both eyes. The majority 
of the patients had 20/20 vision (Table 7). Full-field ERG results showed no 
generalized rod or cone dysfunction.  
Genetic screening of both the ABCA4 and PRPH2 genes by complete 
sequencing of the coding regions confirmed two (expected) disease-causing 
ABCA4 mutations in five patients and one mutation in the remaining three 
patients. No mutations in the PRPH2 gene were found. 
 





Snellen BCVA Fundus Appearance ABCA4 
Mutation(s) OD OS Color FAF 









p. [A1357V] ; 
[G1961E] 
P3 57, M 20/20 20/20 BEM + Flecks BEM + Flecks p. [R2107H] 
P4 10, F 20/30 20/25 BEM + Flecks BEM + Flecks p. [E160*] ; 
[R1108C] 




p. [R2107H] ; 
[E526A] 
P6 19, F 20/25 20/25 BEM BEM p. [R602W] 
P7 26, M 20/20 20/20 BEM BEM p. [R1300*] ; 
[R2106C] 
P8 25, M 20/20 20/40 BEM BEM p. [Q1003*] ; 
[G1961E] 




5.3.2. Structural analysis of the retina 
Fundus photos and FAF imaging 
All patients exhibited either a confined or bull’s eye maculopathy (BEM)-type 
lesion restricted within the vascular arcades on fundus photos (Figures 10 and 
11). Yellow fleck deposits around the central lesions were observed in five 
patients (P1–5). Accompanying macular lesions in FAF imaging varied among 
patients. Round or elliptical BEM lesions with a dark center and hyper-AF border 
were noted in P6, P7 and P8, while mottled fleck patterns where observed in 
P1–5 (Figures 10 and 11). Patients 3 and 4 also exhibited a ring of fluorescent 
granular deposits surrounding the hypo-AF ovoid foveal lesion (Figures 10 and 
11, P3 and P4). 
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Structural analysis of the retina on SD-OCT 
Single horizontal line scans through the fovea and volume SD-OCT scans in 
each patient revealed an abrupt disruption of the EZ band in the parafoveal 
region and thinning of the outer nuclear layer (ONL), with relative sparing of 
the central foveal region. Posterior displacement of the parafoveal inner retinal 
layers and relatively spared fovea with slightly anteriorly bowing ELM and EZ 
bands forming a so-called „flying saucer“ configuration associated with HCQ-
induced retinal toxicity was evident in all patients (see Figures 10 and 11).  
Despite the apparent sparing of the fovea, SD-OCT scans showed some 
abnormalities within this region in all patients. All patients had loss of the IZ and 
thinning of ONL and EZ, except P3, who exhibited normal apparent thickness 
of all retinal layers, and P1, who showed no apparent decrease in ONL thickness 
in the fovea (Figures 10 and 11). Thinning of the RPE-Bruch’s membrane 
complex in the fovea was observed in three patients (P2, P7 and P8). Patient 4 
exhibited a thickened ELM protuberance that delimited a thin layer of spared 
EZ in the fovea.  
The degree of outer retina involvement in the parafoveal region was variable. 
Three patients (P1–3) showed discontinuity/disruption of the EZ band and 
thinning of ONL preserving the ELM. Ellipsoid zone disruption in P1 was seen 
throughout a speckled FAF lesion. Total loss of parafoveal EZ was seen in P4–
8, while P7 and P8 had the most prominent changes, resembling most advanced 
parafoveal atrophy with the ELM loss and the RPE thinning (Figure 11, P7 and 
P8). The RPE thinning in this region also was noted in P1 and P2, while P2 had 
a very confined area of geographic atrophy in the nasal side of the fovea 
(Figure 10, P2). Interdigitation zone loss was present in all patients, becoming 
visible in parafoveal region in three patients (P2, P7 and P8).  
 
 
5.3.3. Lesion formation 
A preceding stage of the transient HCQ retinopathy phenotype in STGD1 was 
observed in P6, who exhibited EZ band loss (optically empty space) in the 
parafoveal region around the central island of preserved and hyper-reflective 
photoreceptor layer (Figure 12, c). Seven months later, the optically empty 
space appeared to collapse, forming a lesion resembling the transient HCQ-






Figure 10. Thinning of the parafoveal region with relative foveal sparing presenting as 
the hydroxychloroquine retinopathy associated parafoveal outer retina thinning 
phenotype in patients with Stargardt disease. Color photograph (a), fundus auto-
fluorescence (b), and spectral-domain optical coherence tomography (c) images of an 
unaffected individual with outer retinal layers defined: the outer nuclear layer (ONL), 
the external limiting membrane (ELM), the ellipsoid zone (EZ), the interdigitation zone 
(IZ) and the retinal pigment epithelium (RPE) (Inset). Yellow pisciform flecks 
accompanying mottling over in the central macula are apparent on color, FAF and SD-
OCT (g, h, i; red arrows). Corresponding SD-OCT scans (f, i, l) reveal abrupt disrup-






Figure 11. Abrupt thinning of the parafoveal region (white arrows), with relative foveal 
sparing, presenting as the hydroxychloroquine retinopathy associated parafoveal outer 
retina thinning phenotype with Stargardt disease, continued. Color photographs (a, d, g, 
j), fundus autofluorescence images (b, e, h, k, n), and spectral-domain optical coherence 
tomography images (c, f, i, l, o) in patients 4, 5, 6, 7 and 8; infrared reflectance image 






Figure 12. Structural development of a lesion resembling the HCQ associated 
parafoveal outer retina thinning phenotype in patient 6. Color (a) and autofluorescence 
(b) images presented with corresponding spectral domain-optical coherence tomography 
scans in both eyes (c). Parafoveal optically empty lesions in each eye (dotted box) are 
apparent bilaterally. A subsequent visit 7 months later (d, e, f) revealed an apparent 
collapse of the inner retinal layers forming abrupt thinning of the parafoveal region 
(white arrows), consistent with an HCQ-induced retinal toxicity presentation. 
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6. DISCUSSION 
STGD1 is the most common inherited macular dystrophy caused by defective 
ABCA4 transporter leading to excessive lipofuscin accumulation, RPE cell and 
photoreceptor degeneration (Molday and Zhang, 2010). The classical phenotype 
in STGD1 is an atrophic-appearing macular lesion with pisciform yellowish 
flecks, but there is a remarkable phenotypic heterogeneity (Michaelides et al., 
2003).  
Today, the modern imaging methods provide us with new possibilities in 
studying the phenotypic expression of the disease (Keane and Sadda, 2014). 
One of such is SD-OCT, which enables to perform in vivo histology and detect 
even very fine structural changes in the retina.  
All our studies used SD-OCT to assess the retinal structural changes and 
phenotypes in STGD1. The universal phenotypic feature in STGD1 is outer 
retinal degeneration and thinning detectable on SD-OCT (Duncker et al., 2014, 
Burke et al., 2011, Park et al., 2015, Ergun et al., 2005), however it has been 
shown that inner retinal changes accompany with photoreceptor loss indicating 
that retina is a complex tissue with different cell types and communications 
(Huang et al., 2014, Genead et al., 2011, Pasadhika et al., 2009).  
 
 
6.1. Early stage retinal structural changes in STGD1 
We have shown for the first time quantitatively in a cohort of patients that, in 
addition to atrophic outer retinal changes, there is an abnormal ELM thickening 
in young STGD1 patients. At the time of the study (Paper I) we found only 2 
case reports in the literature mentioning the ELM thickening in patients with 
STGD1 (Burke et al., 2013, Fujinami et al., 2014). One of them reported a single 
case of a young patient with STGD1 exhibiting an unusual thickening of the 
ELM on SD-OCT in the absence of other functional and structural changes in 
the retina (Burke et al., 2013).  
Our study included 26 young (< 20 years old) STGD1 patients, imaged 
relatively soon after the disease onset, and 30 age-matched controls. The quan-
titative analysis revealed that all patients, except two in whom quantitation was 
not possible, exhibited significantly thicker and hyper-reflective ELM but thinner 
EZ compared with the control individuals. The EZ thinning, representing photo-
receptor abnormalities (Spaide and Curcio, 2011, Wong et al., 2012), was 
expected considering the pathogenesis of the disease, while the ELM thickening 
was somewhat surprising.  
The exact source of band reflectivity on SD-OCT is largely unknown, but it 
has been suggested that mitochondria may partly contribute to the OCT 
visibility, among other structures. Ellipsoid zone represents the ellipsoids of 
photoreceptor inner segments, containing high volume of mitochondria (Spaide 
and Curcio, 2011). The band has been shown to correlate well with the health of 
photoreceptors and the visual function (Wong et al., 2012, Testa et al., 2012, 
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Ergun et al., 2005), while the hyper-reflective band above EZ is thought to 
represent the ELM, which is formed by the apical ends of Müller cells forming 
junctional complexes between each other and photoreceptors (Spaide and 
Curcio, 2011, Staurenghi et al., 2014, Ross and Pawlina, 2011). Therefore, 
several hypotheses can be generated from these findings. First, changes in the 
ELM can be attributed to the (mis)interaction between photoreceptors and Müller 
cell processes or homotypically between Müller cells (Burke et al., 2013). 
Secondly, it has been hypothesized that the ELM thickening and higher ref-
lectivity could be caused by the mitochondria translocation and attachment to 
the ELM in the background of retinal degeneration (Litts et al., 2015).  
Müller cells became reactive to many pathologic stimuli in the retina-
weather extrinsic or intrinsic. In the background of photoreceptor degeneration 
and possible neuroinflammation (Radu et al., 2011, Kohno et al., 2013, Zhou et 
al., 2006) Müller cell activation is vital, protecting the surrounding neurons and 
restoring homeostasis in the retina via various mechanisms, including secretion 
of neurotropic factors, growth factors and cytokines (Reichenbach and Bring-
mann, 2013). Müller cell activation leads to their reactive gliosis (Bringmann et 
al., 2009, Bringmann et al., 2006), which involves hypertrophy, proliferation and 
migration of the glial cells and their processes (Bringmann et al., 2009, Vecino 
et al., 2016). It is known, that retinal degeneration does not cause only photo-
receptor and RPE death, but the process is much more complex and certain 
pattern of retinal remodeling takes place, including glial seal formation composed 
of Müller cell distal processes (Jones and Marc, 2005). However, there are still 
limited data on Müller cell gliosis in retinal dystrophies. In STGD1 we found 
only one histopathological study on two enucleated eyes, which described the 
reactive Müller cell hypertrophy in addition to reduced number of photo-
receptors and the RPE cells (Birnbach et al., 1994). However, some other in 
vivo studies with mammals have demonstrated early Müller cell activation and 
gliosis in retinitis pigmnetosa models. In retinitis pigmentosa RPE65 mutant 
dog model, transient Müller cell activation was noted, interestingly more 
intense in early stages and younger animals possibly due to less advanced 
degenerative changes (Vecino et al., 2016). Retinitis pigmentosa P23H 
(rhodopsin) rat model shows hypertrophy of both Müller cells and astroglia 
indicating to reactive gliosis in the retina (Fernandez-Sanchez et al., 2015). The 
hypertrophic Müller cell apical ends form firework-like structures into the ONL, 
which disappeared in later stages of retinal degeneration (Fernandez-Sanchez et 
al., 2015). All this indicates that the reactive response is probably a transient 
event in a background of less advanced atrophic changes. The same is supported 
by our clinical observation that the ELM prominence is noted in younger patients 
with generally less advanced atrophic changes. Furthermore, we found the ELM 
prominence gradually decrease with increasing patient age (downward sloping 
trend line, r2 = 0.21).  
Whether the extensive ELM thickening detectable on SD-OCT is specific to 
STGD1 needs to be investigated further, but existing studies show that despite 
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the universal reactive gliosis in retinal stress situations, the extent of the process 
is disease specific (Hippert et al., 2015).  
Different retinal dystrophies share common cellular responses to stress, such 
as inflammatory response, oxidative stress and activation of apoptotic pathways 
(Cuenca et al., 2014), but each has also specific factors depending on the etiology 
and pathogenesis. These include rate of cell loss, intercellular interactions or 
local change in the chemical milieu which all may affect Müller cell responses. 
In STGD1 the characteristic pathologic event is increased lipofuscin accumu-
lation, which may contribute to the ELM prominence, furthermore very recently 
the ELM thickening as an early stage abnormality was described in another 
Stargardt-like lipofuscin-associated retinopathy (Palejwala et al., 2016).  
The study has some limitations. The quantitation method, including the 
spatially restricted area of the measurements, image quality, inter subject scan 
normalization, among others, is likely to introduce errors, further necessitating 
more extensive analyses in addition to those that have been previously described 
(Hood et al., 2011, Hood et al., 2009). However, comparable studies have con-
firmed the reproducibility of SD-OCT measurements with built-in caliber tool 
from the instrument (Heidelberg Engineering) used in this study (Yamashita et 
al., 2012). In addition, we calculated the intraclass correlation coefficients for 
the measurements, which showed acceptable agreement between two inde-
pendent measurers, further indicating compatibility.  
It has to be noted, that the patient age was strictly confined to < 20 years. 
Presuming that ELM abnormalities occur in early stages of STGD1, we 
examined a cohort of 26 clinically diagnosed and genetically confirmed patients 
soon after the disease onset. Symptomatic changes indicative of early-onset 
STGD1 typically begin within the first and second decades of life (Michaelides 
et al., 2003). Therefore, the inclusion criteria were limited to those patients first 
examined when aged younger than 20 years. At the time of imaging, most of the 
patients in our cohort had relatively early stage of the disease (Fishman 1 (54%) 
or 2 (46%)) with the mean disease duration of 3.2 years. Therefore, due to our 
selection criteria, we cannot extend these findings to the later-onset disease.  
 
 
6.2. Sub-phenotypes in STGD1 detectable on SD-OCT 
Optical gap phenotype in STGD1 
There are several sub-phenotypes in STGD1 which are best detected on SD-
OCT, one of which is the optical gap phenotype. It represents a focal loss of 
subfoveal photoreceptors leaving an optically empty space detectable by SD-
OCT (Leng et al., 2012, Cella et al., 2009). The phenotype has been associated 
with retinal dystrophies mostly affecting cone photoreceptors, such as rod 
monochromatism (Greenberg et al., 2014) and maculopathies caused by 
mutations in RP1L1 and KCVN2 genes (Park et al., 2010, Sergouniotis et al., 
2012). In the literature, only sporadic cases of the optical gap phenotype in 
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STGD1 have been published (Cella et al., 2009, Leng et al., 2012, Gomes et al., 
2009, Ritter et al., 2013). 
We conducted a study (Paper II), specifically looking for the optical gap 
phenotype in a large cohort of STGD1 patients to assess the structural develop-
ment, possibly deciphering the early effects of ABCA4 dysfunction in this 
phenotypic subgroup, and the genetic background of the phenotype. Further-
more, we were interested in the association between the phenotype and the retinal 
function.  
The analysis of this patient cohort suggests that the development of optical 
gap can be divided into three structural stages over several years. Stage 1 
patients present with disorganization of photoreceptors and intermittent brakes 
in the EZ band forming gap lesion in the subfoveal region. A further spatial 
depletion of the EZ is seen in Stage 2 patients where an expansive subfoveal 
empty cavity is apparent with accompanying decline in visual acuity. Stage 3 
represents a structural collapse of the inner retina into the gap lesion. The 
visibility of the EZ band has been attributed to the photoreceptor integrity 
correlating well with visual function (Wong et al., 2012, Testa et al., 2012), 
therefore patients with Stage 1 optical gap had relatively spared central vision, 
compared with patients exhibiting more severe EZ loss in Stages 2 and 3. All 
patients with the optical gap phenotype and available ffERG recordings had 
normal full-field ERG findings indicating a localized disease and better 
prognosis in terms of visual function (Fujinami et al., 2013a, Zahid et al., 2013, 
Lois et al., 1999). 
Loss of ABCA4 function results in lipofuscin deposition in the RPE cells 
that have phototoxic effects on the RPE cells ultimately leading to its imminent 
death (Sparrow et al., 2000, Sparrow and Boulton, 2005). This mechanism 
supports the current understanding that structural degeneration of the RPE cells 
sequentially precedes that of photoreceptors in STGD1 (Sparrow and Boulton, 
2005, Cideciyan et al., 2004, Glazer and Dryja, 2002). However, there are still 
some controversies in the understanding of exact sequence of disease process 
(Gomes et al., 2009, Duncker et al., 2014, Chen et al., 2011, Song et al., 2015, 
Glazer and Dryja, 2002). In addition to observation by other groups (Gomes et 
al., 2009, Cella et al., 2009, Leng et al., 2012), our study supports the finding 
that the photoreceptors degeneration precedes RPE death in this subgroup of 
patients. First of all, in Stages 1 and 2 the RPE seems relatively intact despite 
the EZ band disruption. Secondly, the mf ERG from nine eyes showed decreased 
responses in the 5° to 15° of retina in the posterior pole. Similar to other mfERG 
studies in STGD1 (Kretschmann et al., 1998, Gomes et al., 2009) the functio-
nally affected areas were much larger than structural changes on SD-OCT or 
FAF, suggesting that functional loss precedes structural changes in these patients. 
Additionally, given that the decreases in mfERG responses have been attributed 
to the influence of the EZ band, a case can be made for early photoreceptor 
dysfunction preceding structural RPE loss in these patients (Testa et al., 2012, 
Gomes et al., 2009). This is further supported by the genetic background of the 
phenotype. We detected that the optical gap phenotype is associated with the 
54 
p.G1961E allele. The p.G1961E allele in homozygous or compound hetero-
zygous state has been associated with a milder, localized disease process that is 
confined to the central macula, often as a bull’s eye lesion, in conjunction with a 
characteristic absence of “dark choroid” on fluorescein angiography (Fishman 
et al., 1999, Cella et al., 2009, Simonelli et al., 2005). The absence of “dark 
choroid” reflects lower levels of lipofuscin accumulation, which was further 
demonstrated with quantitative autofluorescence imaging, showing that FAF 
levels are much lower in STGD1 patients carrying the p.G1961E allele compared 
to non-p.G1961E STGD1 patients (Burke et al., 2014). Low lipofuscin levels 
imply that cone dysfunction probably precedes RPE lipofuscin toxicity in the 
central maculae of p.G1961E patients indicating that a different pathogenetic 
mechanism compared to other STGD1 patients is possible (Burke et al., 2014).  
Furthermore, there is increasing evidence that free all-trans retinal causes 
light-induced photoreceptor degeneration directly even without the presence of 
A2E (Maeda et al., 2009, Maeda et al., 2012, Chen et al., 2012, Maeda et al., 
2014), therefore this pathogenic mechanism probably predominates in this 
subgroup of STGD1 patients. Our results of the structural behavior and the 
discussion of disease sequence were further supported by the findings from Sisk 
et al (Sisk and Leng, 2014), who published their study about the same time as 
we did, however their cohort was based on ophthalmoscopic findings and, in 
our opinion, contained only two patients with an evident optical gap phenotype. 
 
A subtype of foveal sparing phenotype in STGD1 
Another phenotype in STGD1 is foveal sparing, best detectable by SD-OCT. In 
contrast to the optical gap phenotype, where early foveal cone involvement 
takes place, foveal sparing phenotype on the contrary exhibits a relatively intact 
fovea, preserving cones and good visual function (van Huet et al., 2014, 
Fujinami et al., 2013d). We detected a variant of foveal sparing phenotype in 
STGD1 associated mostly with HCQ retinopathy. The phenotype is described as 
a thinning of the outer retinal layers around the preserved region of the ellipsoid 
zone forming “flying saucer” configuration. Therefore, the phenotype is collo-
quially called a “flying saucer” sign in HCQ retinopathy (Chen et al., 2010, 
Marmor, 2012, Ascaso et al., 2013, Tailor et al., 2012).  
We detected 8 STGD1 patients with similar SD-OCT phenotype, 3 of whom 
exhibited also HCQ retinopathy-like BEM lesions on FAF and funduscopy, 
showing that Stargardt disease may phenocopy the HCQ retinopathy (Paper III). 
The majority of the patients did not report any visual symptoms and had 
excellent visual acuity, which is consistent with the relatively spared fovea with 
intact photoreceptors. Our study confirmed that despite similarities in SD-OCT 
imaging in these patients, a valuable imaging tool in differentiating STGD1 
from HCQ retinopathy is FAF, because most of the patents exhibit characte-
ristic flecks, although not always, as 3 patients revealed classical BEM lesion, 
without any apparent hyper-AF flecks.  
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Spectral-domain OCT revealed variable severity of retinal atrophy in the 
parafoveal region, while five younger patients (P4–8) showed also qualitatively 
thickened and hyper-reflective ELM, in consistent with the first study (Paper I), 
while in 3 older patients the prominence was not that obvious, indicating to the 
importance of this finding in younger STGD1 patients. Based on our clinical 
observation the ELM prominence is not evident in HCQ retinopathy, but it has 
to be noted that patients with HCQ toxic maculopathy are generally older. 
Furthermore, despite the relatively spared fovea in these STGD1 patients, all 
patients had the loss of IZand majority exhibited some degree of ONL thinning 
uncommon in an early or moderate stage of HCQ retinopathy (Marmor, 2012).  
The development of the HCQ retinopathy-like SD-OCT phenotype was 
noted in one patient, where similar optically empty lesion as described in Paper 
2 formed around a central island of preserved photoreceptors later collapsing 
and leaving a phenotype resembling the HCQ retinopathy. 
The exact mechanism of HCQ retinal toxicity is not fully understood, how-
ever both, STGD1 and HCQ, share some common mechanistic features. It has 
been shown that HCQ may cause lysosomal dysfunction leading to lipofuscin 
accumulation (Mahon et al., 2004, Sundelin and Terman, 2002), while STGD1 
is caused by a defective ABCA4 transporter, which similarly leads to lipofuscin 
accumulation (Molday and Zhang, 2010). The lipofuscin is toxic to the RPE 
cells and photoreceptors, leading to the outer retinal degeneration (Sparrow et 
al., 2000, Sparrow and Boulton, 2005). Both retinopathies show initially an 
increased FAF signal (Burke et al., 2014, Kellner et al., 2006, Kellner et al., 
2008), referring to increased lipofuscin accumulation, and later bull’s eye-like 
lesion, when the RPE atrophy develops. However, in HCQ retinopathy the 
photoreceptor loss precedes the RPE atrophy (Rodriguez-Padilla et al., 2007, 
Chen et al., 2010, Marmor, 2012, Kellner et al., 2009), while in STGD1, the 
precise sequence of RPE/photoreceptor loss is less clear (Cideciyan et al., 2004, 
Glazer and Dryja, 2002, Burke et al., 2011, Gomes et al., 2009). All patients 
from our cohort had some degree of visible RPE involvement, with pigment 
mottling, flecks or BEM, indicating much earlier RPE damage than would be 
expected in HCQ retinopathy.  
It has been proposed, that the ABCA4 gene could be involved in the 
development of HCQ-induced retinopathy (Shroyer et al., 2001). The incidence 
of toxic retinopathy in HCQ users is between 0.5–7.5% (Marmor et al., 2011, 
Melles and Marmor, 2014), and it is not fully understood why some users are 
predisposed to the toxicity. Shroyer et al found disease causing missense variants 
in the ABCA4 gene in two of eight patients thought to have HCQ maculopathy 
due to the history of HCQ use and classical appearance of HCQ maculopathy 
lacking in STGD1-associated dark choroid and lipofuscin flecks. These variants 
were not present in the control group, suggesting that carrying an ABCA4 
mutation may increase the risk of HCQ retinopathy (Shroyer et al., 2001). In 
fact, one of the two patients was homozygous for missense mutation p.R2107H, 
but was thought to have HCQ maculopathy due to the classical appearance of 
this retinopathy. This mutation was also present in two of eight patients in our 
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cohort with phenotypes resembling HCQ retinopathy. Moreover, these patients 
in our study (Paper 3) are of African descent and the p.R2107H variant was 
recently described as the most prevalent disease causing mutation in African-
American patients with STGD1, exhibiting disease with milder phenotype and 
later-onset (Zernant et al., 2014a). Interestingly, a more recent study has found, 
on the contrary, that some ABCA4 missense variants may have a protective 
effect reducing the susceptibility to develop toxic retinopathy under chloroquine 
treatment (Grassmann et al., 2015). 
 
 
6.3. Genotype-phenotype associations in STGD1 
Genotype-phenotype associations are difficult to assess and detect in STGD1. 
First of all, there is remarkable allelic heterogeneity in STGD1 and secondly, 
harboring two different alleles in autosomal-recessive disorder makes it difficult 
to determine the combination effect, especially if the number of known ABCA4 
disease-associated alleles is >1000. Therefore, large databases are needed with 
genotype and phenotype information, and possibly also some functional studies 
to detect the effects of individual alleles. However, we detected genotype-
phenotype association in the optical gap phenotype. By genetic analysis of 
patients with the optical gap phenotype we confirmed that all were compound 
heterozygous for ABCA4 mutations. Interestingly, the p.G1961E variant was 
present in 10 of 11 unrelated cases (91%). The p.G1961E mutation is the most 
frequent disease associated ABCA4 allele seen in approximately 10% of STGD1 
patients of European origin (Burke et al., 2012a). This fraction was almost the 
same in our cohort of 179 patients, including 157 unrelated individuals (42/157; 
13.4%), but remarkably higher in patients with the optical gap phenotype (46.7% 
vs. 13.4%, p < 0.0001). It has to be noted, however, that while the optical gap 
phenotype is definitely associated with the p.G1961E variant, the reverse is not 
the case since a larger fraction (32 unrelated individuals) who harbored the 
p.G1961E allele did not present with the optical gap. Fourteen of these indi-
viduals were clinically characterized at the same age after onset as the optical 
gap group. Of the other disease-associated ABCA4 alleles compound hetero-
zygous with p.G1961E, the p.L541P mutation, presenting alone or as a complex 
allele with the p.A1038V variant, was observed in seven cases (four unrelated) 
with the optical gap while only once in patients without the phenotype. How-
ever, due to a relatively small size of the optical gap cohort we cannot make an 
unequivocal conclusion about the association of this allele with the optical gap 
phenotype. With the exception of P13, the optical gap was not observed in the 
SD-OCT scans of any other non-p.G1961E patients (n = 131) whose age at time 
of examination, age of onset and estimated disease duration were not statisti-
cally different from those of the p.G1961E (n = 48) patients. Therefore the 
p.G1961E variant, maybe sometimes together with the p.L541P or p. (L541P; 
A1038V) allele, is associated with the optical gap phenotype. It is also interesting 
that p.L541P and p.(L541P; A1038V) alleles have been considered as severe 
alleles causing misfolding and reduction of ATPase activity of ABCA4 leading 
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to severe phenotypic expression (Zhang et al., 2015, Cideciyan et al., 2009), 
while in this case, the combination with p.G1961E allele, the phenotype in 
rather mild, indicating that the p.G1961E might have a “dominant” effect over 
the second mutation (Burke and Allikmets, 2013, Burke et al., 2014). 
Genotype-phenotype association was not detected in the foveal sparing 
phenotype. However, the number of patients was very small. A study by 
Fujinami et al reported slightly higher frequency of p.R2030Q variant and lower 
incidence of p.G1961E ABCA4 variant in STGD1 patients with foveal sparing 
phenotype, however the association was not statistically significant (Fujinami et 
al., 2013d). None of our patients as well as patients in another study (van Huet 
et al., 2014) harbored the p.R2030Q variant. An etiological connection between 
foveal sparing and ABCA4 is further weakened by the incidence of foveal 
sparing phenotype in other genetically distinct retinal degenerative diseases 
such as PRPH2 pattern dystrophy and AMD (Boon et al., 2008, Schmitz-
Valckenberg et al., 2009, Duncker et al., 2015). In addition, two patients in this 
cohort harbored the p.G1961E allele, which would explain the milder course of 
the disease, but it was somewhat surprising in the foveal sparing phenotype, as 
the allele is associated predominantly with the central macular disease with cone 
involvement (Cella et al., 2009). The same was demonstrated in Paper 2 that the 
optical gap phenotype with cone-predominant change is associated with 
p.G1961E allele. Furthermore, in another study with foveal sparing phenotype 
(van Huet et al., 2014), none of the patients harbored p.G1961E allele and in a 
cohort of 40 patients with preserved foveal FAF only one patient carried the 
p.G1961E mutation as opposed to higher p.G1961E allele frequency in non-
foveal sparing patients (1.6% vs 6.1%) (Fujinami et al., 2013d). Therefore, in 
agreement with other studies there are probably other genetic or non-genetic 
factors contributing to foveal sparing phenomenon, which need to be further 



















1. In addition to significant thinning of the photoreceptor-associated ellipsoid 
zone layer, there is a statistically significant thickening of the external limiting 
membrane in young STGD1 patients compared to the age-matched controls. 
The finding probably reflects a transient hypertrophy of retinal Müller cells 
in response to cellular stress at the photoreceptor level, and could clinically 
be an important early stage disease marker, holding a diagnostic potential in 
early diagnosis of the STGD1. 
2. The optical gap phenotype in STGD1 can be structurally divided into 3 
progressive developmental stages. Initially there is mild subfoveal disruption 
of the EZ followed by progressive expansion of the EZ loss resulting in 
optically empty space devoid of foveal photoreceptors. At the later stage of 
the disease, the optically empty space collapses followed by progressive 
neuroretinal and the RPE cell atrophy. In contrast to the common under-
standing, that the first cells being affected in STGD1 are the RPE cells, our 
study seems to support the finding of some other groups, that in the STGD1-
associated optical gap phenotype, photoreceptor loss sequentially precedes 
the RPE degeneration, suggesting a different pathogenetic mechanism in this 
subgroup of patients.  
The visual acuity in these patients correlated well with the EZ integrity, 
therefore patients with Stage 1 optical gap had relatively spared central 
vision, compared with the patients having more severe ellipsoid zone loss in 
Stage 2 and Stage 3. All patients with the optical gap phenotype and available 
ffERG recordings  had normal ffERG responses, indicating a localized 
disease process and better prognosis in terms of visual function.  
We detected that STGD1 could phenocopy HCQ toxic retinopathy. A 
variant of foveal sparing phenotype in STGD1 mimics an OCT sign associated 
with HCQ retinal toxicity, also called a “flying-saucer” sign. Furthermore, in 
addition to the similar SD-OCT phenotype presentation, some of the patients 
presented with classical HCQ retinopathy-like bull’s eye lesion on FAF and 
funduscopy lacking STGD1-characteristic flecks, therefore making pheno-
typic differentiation of these retinopathies difficult. Consequently, in more 
ambiguous cases ABCA4 screening should be considered to prevent possible 
misdiagnosis. 
The majority of patients with the variant of “foveal sparing” phenotype 
were asymptomatic with very good visual acuity due to the preserved foveal 
photoreceptors. All the patients, with available ERG recordings, had normal 
ffERG responses. 
3. The optical gap phenotype in STGD1 is highly associated with p.G1961E 
mutation in ABCA4. The allele frequency of p.G1961E allele in patients with 
the optical gap phenotype was 46.7%, while in the entire STGD1 cohort of 
179 patients (157 unrelated individuals) it was 13.4%, showing statistically a 
highly significant difference (p < 0.0001). 
59 
Stargardt disease exhibits remarkable phenotypic heterogeneity. Despite 
Mendelian inheritance, genotype-phenotype associations are difficult to detect 
due to the large number of disease causing mutations. However, modern retinal 
imaging methods enable clinicians and researchers to expand the knowledge of 
disease expression, and increase the possibility to detect the genotype-
phenotype associations. Detailed phenotypic descriptions and dynamic 
assessment via multimodal imaging as well as detecting new genotype-
phenotype associations potentially improve the planning of pharmacological, 
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9. SUMMARY IN ESTONIAN 
Autosoom-retsessiivne Stargardti tõbi: fenotüübiline heterogeensus ja 
genotüübi-fenotüübi seosed 
Stargardti tõbi (STGD1) on kõige sagedasem pärilik kollatähni düstroofia, mille 
esinemissageduseks hinnatakse olevat 1:8000–1:10 000 (Michaelides et al., 
2003). Haigus on põhjustatud ABCA4 geeni defektist, mille tulemusena häirub 
fotoretseptorites paikneva ning visuaaltsüklis olulise ABCA4 transporteri töö 
(Allikmets et al., 1997b, Molday and Zhang, 2010). Haiguse tulemusena 
koguneb võrkkesta pigmentepiteeli (RPE) rakkudesse toksiline ühend (lipo-
fustsiin), mis viib RPE rakkude ja fotoretseptorite kaole. Samas on siiani dis-
kussiooniks, kas primaarselt hävivad RPE rakud, viies sekundaarselt foto-
retseptorite kaole, või toimub fotoretseptorites juba varem destruktiivseid 
kahjustusi (Cideciyan et al., 2004, Sparrow and Boulton, 2005, Duncker et al., 
2014, Gomes et al., 2009).  
Arvestades, et STGD1 on autosoom-retsessiivse pärilikkusega haigus ning 
kirjeldatud on enam kui 1000 haigustekkelise mutatsiooni, esineb kliinilises 
pildis ja haiguse väljakujunemise eas väga suur varieeruvus (Burke and Tsang, 
2011). Fenotüübiliselt on STGD1 haigeid jaotatud vastavalt võrkkesta haara-
tusele nelja staadiumisse, kus esimene staadium väljendub isoleeritud kollatähni 
haigusena ja neljas staadium laiaulatusliku korioretinaalse atroofiana (Fishman, 
1976). Elektrofüsioloogiliselt on samuti kirjeldatud erinevaid STGD1 fenotüüpe 
(Lois et al., 2001). Esineb haigeid, kellel on normaalne kepikeste ja kolvikeste 
massvastus, kuid ka neid, kellel kolvikeste või nii kolvikeste kui ka kepikeste 
funktsioon on oluliselt langenud (Lois et al., 2001). Haigus on enamasti vara-
jase algusega ning sümptomid tekkivad tavaliselt teisel eludekaadil, kuid esineb 
ka hilis-algusega STGD1, kus haiguse sümptomid avalduvad tunduvalt hiljem 
(Westeneng-van Haaften et al., 2012). 
Võrkkesta muutuste detailseks hindamiseks on kasutusel mitmeid võrkkesta 
kuvamisuuringuid, millest olulisemad on optiline koherentne tomograafia (SD-
OCT) ja silmapõhja autofluorestsents- uuring (FAF). Esimene võimaldab 
visualiseerida erinevaid võrkkesta kihte, kuvades in vivo histoloogilise pildi, 
ning teine, autofluorestsents kuvamisuuring, võimaldab hinnata lipofustsiini 
distributsiooni ja RPE rakkude terviklikkust (Boon et al., 2008). Klassikaliselt 
on varajasteks STGD1 iseloomulikeks kliinilisteks leidudeks tähnilised kollakad 
ladestused ja kollatähni atroofia, mis võrkkesta kuvamisuuringutel väljenduvad 
lipofustsiini kogunemisest tekkiva autofluorestsents-signaali intensiivistumisena 
ja kollatähni piirkonna välisreetina atroofiana (Michaelides et al., 2003, Cide-
ciyan et al., 2004, Huang et al., 2014). Samas võimaldavad detailsed kuvamis-
uuringud laiendada STGD1 fenotüübilist spektrit veelgi. Nüüdseks on STGD1 
puhul kirjeldatud nii „foveat säilitavat“ (ingl.k foveal sparing) fenotüüpi kui ka 
fovea tühimikku (ingl.k optical gap; foveal cavitation) (Fujinami et al., 2013d, 
van Huet et al., 2014, Leng et al., 2012). Kumbki fenotüüp ei ole spetsiifiline 
STGD1, vaid on kirjeldatud mitmete erinevate võrkkesta düstroofiate korral 
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(Greenberg et al., 2014, Park et al., 2010, Sergouniotis et al., 2012). Foveat 
säilitava fenotüübi korral püsib võrkkesta terava nägemise punkt (fovea) suhte-
liselt kaua muutumatuna, vaatamata küllalt väljendunud leiule mujal võrkkestas, 
mistõttu säilib nägemisteravus suhteliselt kaua (van Huet et al., 2014). Fovea 
tühimik on aga SD-OCT-l ilmestuv fenotüüp, kus fovea fotoretseptorite kaost 
tekkib struktuurne tühimik fovea piirkonna võrkkesta väliskihti (Leng et al., 
2012).  
Genotüübi-fenotüübi seoseid on STGD1 puhul keeruline leida ja analüüsida, 
kuna esineb väga suur alleelne heterogeensus ning sama alleelse kombinat-
siooniga patsiente esineb harva. Lisaks võib fenotüüp olla küllalt erinev ka sama 
alleelse kombinatsiooniga patsientidel, viidates haigust modifitseerivatele 
geenidele või keskkonna faktoritele (Lois et al., 1999, Michaelides et al., 2007). 
Varasemad uuringud on viidanud, et fenotüübi raskuse määrab ära mutatsiooni 
mõju ABCA4 aktiivsusele, samas ei pea funktsiooni hüpotees alati paika (Sun 
et al., 2000, Shroyer et al., 1999, van Driel et al., 1998, Cideciyan et al., 2009, 
Burke et al., 2012b).  
Üks enim uuritud ja levinumaid ABCA4 mutatsioone on p.G1961E. Kliini-
lised uuringud on näidanud, et kirjeldatud mutatsioon põhjustab nii liithetero-
sügootses kui ka homosügootses olekus enamasti tagasihoidlikumat kliinilist 
leidu (Cella et al., 2009, Burke et al., 2012a). Nendel haigetel algab haigus tava-
liselt vanemas eas, avaldudes enamasti nn „härjasilma“ meenutava kollatähni 
atroofiana, kusjuures kepikeste ja kolvikeste massvastus on normis (Cella et al., 
2009). Kvantitatiivse autofluorestsentsuuringuga on näidatud, et p.G1961E 
mutatsiooniga esineb tagasihoidlikum lipofustsiini kogunemine, viidates võima-
likule alternatiivsele patogeneesi mehhanismile (Burke et al., 2014). 
 
Uurimistöö eesmärgid 
• Analüüsida varaseid võrkkesta struktuurimuutuseid noortel STGD1 haigetel. 
• Leida, kirjeldada ja analüüsida optilisel koherentsel tomograafial ilmestuvaid 
STGD1 fenotüüpe ja hinnata nende fenotüüpidega kaasnevat võrkkesta 
funktsiooni. 
• Leida ja kirjeldada võimalikke Stargardti tõvega esinevaid genotüübi-feno-
tüübi seoseid. 
 
Patsiendid ja meetodid 
Uurimustöös kasutati Columbia Ülikooli silmakliiniku pärilike võrkkesta ehk 
reetina düstroofiate andmebaasi, mis sisaldab endas ka geneetiliselt kinnitatud 
STGD1 haigeid. Andmebaasis oli kahe esimese uuringu teostamise ajaks 179 
STDG1 haiget, kellele olid teostatud nii SD-OCT kui ka FAF uuringud. Kuna 
andmebaas on ajas pidevalt täienev, siis kolmanda uuringu teostamise ajaks oli 
vastavate võrkkesta kuvamisuuringutega STGD1 haigete arv 200.  
Võrkkesta struktuuri analüüsimiseks kasutasime silmapõhja fotosid, SD-
OCT ja FAF kuvamisuuringuid. Funktsiooni hindamiseks kasutasime nägemis-
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teravuse määramist, multifokaalset ja täisvälja elektroretinograafiat (ERG). 
Geenianalüüs oli esimesesse uuringusse kaasatud patsientidel teostatud ABCA4 
geenikiibiga või järgmise põlvkonna ja Sangeri sekveneerimisega. Teise ja 
kolmandasse uuringusse kaasatud patsientidel oli geenianalüüs teostatud vaid 
järgmise põlvkonna ja Sangeri sekveneerimisega.  
Kuna esimeses uuringus soovisime hinnata varaseid võrkkesta struktuuri-
muutuseid ning STGD1 puhused sümptomid kujunevad välja tavaliselt 
20ndateks eluaastateks, siis kaasasime uuringusse kõik STGD1 haiged, kelle 
võrkkesta struktuurianalüüsiks vajalikud kuvamisuuringud olid teostatud enne 
20. eluaastat (keskmine haiguskestvus oli 3,2 a) . Kokku leidsime 179st haigest 
26 vastava kriteeriumile vastavat STGD1 juhtu (keskmine vanus 12,9 a; vahe-
mik 5–19 a). Haigetel mõõdeti ja analüüsiti SD-OCT piltidel võrkkesta ellip-
soidtsooni (iseloomustab fotoretseptorite terviklikkust) ja välise piirimembraani 
paksust ja reflektiivsust kasutades Heidelberg Explorer tarkvara ja ImageJ 
programmi. Tulemusi võrreldi 30 kontrolluuritava (keskmine vanus 12,5 a; 
vahemik 4–20 a) võrkkesta vastavate parameetritega. 
Teises uuringus uurisime fovea tühimikuga STGD1 haigete fenotüübi dü-
naamilist kujunemist, mõju võrkkesta funktsioonile ning mutatsioonide profiili 
(ehk genotüübi-fenotüübi seost). Vaadates läbi 179 STGD1 haige SD-OCT 
ülesvõtted, leidsime 15 haiget, kellel esines kirjeldatud fenotüüp. 
Kolmandas uuringus kirjeldasime ja analüüsisime SD-OCT ilmestuvat foveat 
säilitava fenotüübi varianti, mida siiani on seostatud hüdroksüklorokviin (HCQ) 
toksilise võrkkesta muutusega (retinopaatiaga). Vaadates läbi 200 STGD1 haige 
SD-OCT pildid, leidsime 8 vastava fenotüübiga haiget. Analüüsisime ja kirjel-
dasime leitud haigete kuvamisuuringute, funktsiooni ja ABCA4 geeniuuringute 
tulemusi. 
 
Peamised tulemused ja järeldused 
1) Lisaks klassikalisele seisukohale, kus STGD1 haigetel tekkib võrkkesta 
väliskihtide atroofia, näitasime, et noortel STGD1 haigetel esineb lisaks 
võrkkesta fotoretseptoreid iseloomustava kihi (ellipsoidtsooni) õhenemisele 
võrkkesta välise piirimembraani statistiliselt oluline paksenemine võrreldes 
kontrollgrupiga. Leid võib viidata võrkkesta Mülleri rakkude mööduvale 
hüpertroofiale vastusena fotoretseptorite tasandil esinevale stressile. Välise 
piirimembraani paksenemine võib olla STGD1 varajaseks kliiniliseks 
markeriks, mis omab kliinilist potentsiaali diagnoosimaks haigust varases 
faasis, kui tüüpiline STGD1 iseloomulik fenotüüp ei pruugi olla veel välja 
kujunenud. 
2) Võrkkesta kuvamisuuringute analüüsil saab STGD1 esinevat fovea tühi-
mikku jaotada 3 arengustaadiumisse. Algfaasis esineb kerge fovea aluse 
ellipsoidtsooni granulaarsus, mis progresseerudes viib selge tühimiku moo-
dustumiseni. Lõppfaasis tühimik kaob, millele järgneb neuroreetina ja RPE 
atroofia. Sarnaselt mitmetele teistele uuringutele näitasime ka meie, et 
klassikaline arusaam STGD1 patogeneesist, kus primaarselt esineb lipofust-
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siinist põhjustatud RPE atroofia, millele järgneb sekundaarne fotoretseptorite 
kadu, ei kehti kõikidele STGD1 haigetele. Kirjeldatud fenotüübiga haigetel 
esineb primaarselt just fotoretseptorite kadu, viidates võimalikule alterna-
tiivsele patogeneesimehhanismile. 
 Kirjeldatud struktuuimuutusega patsientidel korelleerub nägemisteravus 
ellipsoidtsooni terviklikkusega, seetõttu on 1. staadiumi fovea tühimikuga 
patsientidel nägemisteravus suhteliselt vähe langenud erinevalt 2. ja 3. 
staadiumist, kus ellipsoidtsoon on rohkem haaratud. Kõigil fovea tühimikuga 
STGD1 haigetel, kellel oli ERG tehtud, olid täisvälja ERG vastused normis, 
viidates lokaalsele haigusprotsessile ning paremale haiguse prognoosile. 
Stargardti tõbi võib fenokopeerida HCQ toksilist võrkkesta muutust, 
omades SD-OCT uuringul iseloomulikku konformatsiooni. Tekkib nn „foveat 
säilitava“ fenotüübi variant, mille tulemusena on kollatähni teravanägemise 
punktis võrkkest suhteliselt hästi säilinud, kusjuures patsiendid on avasta-
mise hetkel enamasti sümptomivabad ja väga hea nägemisteravusega. Kolmel 
patsiendil esines ka klassikaline „härjasilma“ meenutav atroofiline ala ilma 
nähtavate STGD1 iseloomulike lipofustsiini ladestusteta, mistõttu võib 
haiguse diferentseerimine toksilisest HCQ retinopaatiast fenotüübiliselt olla 
pea võimatu. Sellest tulenevalt tuleks keerukamatel juhtudel kaaluda ka 
ABCA4 skriinimist, et välistada STGD1. Kõigil haigetel, kelle oli tehtud 
ERG, olid täisvälja ERG vastused normis.  
 
3) Fovea tühimik on STGD1 korral tugevalt seotud p.G1961E mutatsiooniga 
ABCA4 geenis. Fovea tühimikuga haigete hulgas oli p.G1961E alleeli sage-
dus 46,7%, samas kui kogu STGD1 kohordis oli alleeli sagedus 13,4% 
(p < 0.0001). 
 
Stargardti tõve iseloomustab märkimisväärne fenotüübiline heterogeensus. 
Kasutades kaasaegseid võrkkesta kuvamisuuringuid, analüüsisime võrkkesta 
väliskihtide varajasi struktuurimuutuseid, SD-OCT-l ilmestuvaid fenotüüpe ja 
kirjeldasime genotüübi-fenotüübi seost STGD1 haigetel. Fenotüüpide detailne 
iseloomustamine, dünaamika hindamine ja genotüübi-fenotüübi seoste 
kirjeldamine võiks potentsiaalset paremini aidata planeerida ja analüüsida 
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